Scienture (SCNX) S-1/A3 Feb 20IPO registration (amended)Financial data

Company Profile

Document and Entity Information

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2019
Document And Entity Information
Entity Registrant Name	TRXADE GROUP, INC.
Entity Central Index Key	0001382574
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No.2
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Current Assets
Cash	$ 3,359,288	$ 869,557	$ 183,914
Accounts Receivable, net	710,289	433,627	319,467
Inventory	63,316	79,966
Prepaid Assets	181,922	82,927	102,095
Other Assets			2,000
Total Current Assets	4,314,815	1,466,077	607,476
Property Plant and Equipment, Net	11,256	15,006
Other Assets
Deposits	21,636	20,531	10,000
Right of use leased assets	780,843
Goodwill	725,973	725,973
Total Assets	5,854,523	2,227,587	617,476
Current Liabilities
Accounts Payable	397,987	400,544	106,084
Accrued Liabilities	151,096	138,323	156,961
Current Portion Lease Liabilities	84,050
Short Term Notes Payable			10,587
Short Term Convertible Notes Payable		181,500
Short Term Notes Payable - Related Parties	222,552
Short Term Convertible Notes Payable - Related Parties	100,000	140,000	251,725
Total Current Liabilities	955,685	860,367	525,357
Long Term Liabilities
Convertible Notes Payable			181,500
Notes Payable - Related Parties	300,000	522,552	222,552
Other Long-term Liabilities - Leases	708,289
Total Liabilities	1,963,974	1,382,919	929,409
Shareholders' Equity
Series A Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; none issued and outstanding as of September 30, 2019, December 31, 2018 and December 31, 2017 respectfully
Common Stock, $0.00001 par value; 100,000,000 shares authorized; 38,636,459 and 33,285,827 shares issued and outstanding, as of September 30, 2019, December 31, 2018 and December 31, 2017 respectively	386	332	320
Additional Paid-in Capital	11,790,463	8,955,411	7,807,860
Retained Deficit	(7,900,300)	(8,111,075)	(8,120,113)
Total Shareholders' Equity	3,890,549	844,668	(311,933)
Total Liabilities and Shareholders' Equity	$ 5,854,523	$ 2,227,587	$ 617,476

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Series A Preferred stock, par value	$ 0.00001	$ 0.00001	$ 0.00001
Series A Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Series A Preferred stock, shares issued
Series A Preferred stock, shares outstanding
Common stock, par value	$ 0.00001	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	38,636,459	33,285,827	31,985,827
Common stock, shares outstanding	38,636,459	33,285,827	31,985,827
Short Term Notes Payable [Member]
Short-term notes payable, discount		$ 0	$ 152

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Consolidated Statements of Operations - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenues	$ 2,311,426	$ 847,471	$ 5,740,361	$ 2,538,082	$ 3,831,778	$ 2,931,280
Cost of Sales	1,000,917	2,345	2,119,894	2,345	449,049
Gross Profit	1,310,509	845,126	3,620,467	2,535,737	3,382,729	2,931,280
Operating Expenses
General and Administrative	1,132,656	753,297	3,138,150	2,313,734	3,470,345	2,536,185
Operating Income (Loss)	177,853	91,829	482,317	222,003	(87,616)	395,095
Other Income	25,275	22,500	25,275	22,500	161,639	67,500
Investment Loss	(162,178)		(250,000)
Loss on Extinguishment of Debt		(7,444)		(7,444)	(7,444)	(16,556)
Interest Expense	(13,385)	(12,636)	(46,817)	(40,028)	(57,541)	(157,056)
Net Income	$ 27,565	$ 94,249	$ 210,775	$ 197,031	$ 9,038	$ 288,983
Net Income per Common Share - Basic:	$ 0	$ 0	$ 0.01	$ 0.01	$ 0	$ 0.01
Net Income per Common Share -Diluted:	$ 0	$ 0	$ 0.01	$ 0.01	$ 0	$ 0.01
Weighted average Common Shares Outstanding Basic	34,489,969	32,083,629	34,370,522	32,083,629	32,260,622	31,955,416
Weighted average Common Shares Outstanding Diluted	36,286,487	34,737,964	36,167,040	34,732,540	34,958,502	34,086,251

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2016		$ 316	$ 7,260,723	$ (8,409,096)	$ (1,148,057)
Balance, shares at Dec. 31, 2016		31,660,827
Options Expense			267,835		267,835
Common Stock Issued for cash		$ 3	249,997		250,000
Common Stock Issued for cash, shares		250,000
Common Stock Issued for Services		$ 1	12,499		12,500
Common Stock Issued for Services, shares		50,000
Warrant Expense
Warrants issued for Debt Amendment			16,556		16,556
Warrants Exercised			250		250
Warrants Exercised, shares		25,000
Net Income				288,983	288,983
Balance at Dec. 31, 2017		$ 320	7,807,860	(8,120,113)	(311,933)
Balance, shares at Dec. 31, 2017		31,985,827
Options Expense			37,456		37,456
Net Income				82,269	82,269
Balance at Mar. 31, 2018		$ 320	7,845,316	(8,037,844)	(192,208)
Balance, shares at Mar. 31, 2018		31,985,827
Balance at Dec. 31, 2017		$ 320	7,807,860	(8,120,113)	(311,933)
Balance, shares at Dec. 31, 2017		31,985,827
Warrant Expense
Net Income					197,031
Balance at Sep. 30, 2018		$ 323	8,248,349	(7,923,082)	325,590
Balance, shares at Sep. 30, 2018		32,285,827
Balance at Dec. 31, 2017		$ 320	7,807,860	(8,120,113)	(311,933)
Balance, shares at Dec. 31, 2017		31,985,827
Options Expense			169,828		169,828
Common Stock Issued for cash		$ 12	799,988		800,000
Common Stock Issued for cash, shares		1,300,000
Warrant Expense
Warrants issued for Debt Amendment			7,444		7,444
Warrants for Acquisition of Community Specialty Pharmacy, LLC			170,291		170,291
Net Income				9,038	9,038
Balance at Dec. 31, 2018		$ 332	8,955,411	(8,111,075)	844,668
Balance, shares at Dec. 31, 2018		33,285,827
Balance at Mar. 31, 2018		$ 320	7,845,316	(8,037,844)	(192,208)
Balance, shares at Mar. 31, 2018		31,985,827
Options Expense			50,616		50,616
Net Income				20,513	20,513
Balance at Jun. 30, 2018		$ 320	7,895,932	(8,017,331)	(121,079)
Balance, shares at Jun. 30, 2018		31,985,827
Options Expense			44,976		44,976
Common Stock Issued for cash		$ 3	299,997		300,000
Common Stock Issued for cash, shares		300,000
Warrants issued for Debt Amendment			7,444		7,444
Net Income				94,249	94,249
Balance at Sep. 30, 2018		$ 323	8,248,349	(7,923,082)	325,590
Balance, shares at Sep. 30, 2018		32,285,827
Balance at Dec. 31, 2018		$ 332	8,955,411	(8,111,075)	844,668
Balance, shares at Dec. 31, 2018		33,285,827
Options Expense			35,979		35,979
Common Stock issued for convertible debt and accrued interest		$ 4	211,979		211,983
Common Stock issued for convertible debt and accrued interest, shares		423,966
Warrants Exercised		$ 1	165		166
Warrants Exercised, shares		16,666
Net Income				125,229	125,229
Balance at Mar. 31, 2019		$ 337	9,203,534	(7,985,846)	1,218,025
Balance, shares at Mar. 31, 2019		33,726,459
Balance at Dec. 31, 2018		$ 332	8,955,411	(8,111,075)	844,668
Balance, shares at Dec. 31, 2018		33,285,827
Warrant Expense					26,363
Net Income					210,775
Balance at Sep. 30, 2019		$ 386	11,790,463	(7,900,300)	3,890,549
Balance, shares at Sep. 30, 2019		38,636,459
Balance at Mar. 31, 2019		$ 337	9,203,534	(7,985,846)	1,218,025
Balance, shares at Mar. 31, 2019		33,726,459
Options Expense			64,011		64,011
Net Income				57,981	57,981
Balance at Jun. 30, 2019		$ 337	9,267,545	(7,927,865)	1,340,017
Balance, shares at Jun. 30, 2019		33,726,459
Options Expense			41,604		41,604
Common Stock Issued for cash		$ 49	2,454,951		2,455,000
Common Stock Issued for cash, shares		4,910,000
Warrant Expense			26,363		26,363
Net Income				27,565	27,565
Balance at Sep. 30, 2019		$ 386	$ 11,790,463	$ (7,900,300)	$ 3,890,549
Balance, shares at Sep. 30, 2019		38,636,459

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Operating Activities:
Net Income	$ 210,775	$ 197,031	$ 9,038	$ 288,983
Adjustments to reconcile net income to net cash provided by operating activities:
Stock Issued for Services				12,500
Depreciation Expense	3,750
Options expense	141,594	133,048	169,828	267,835
Warrant Expense	26,363
Bad Debt Expense	6,084	2,271	2,271
Loss on extinguishment of Debt		7,444	7,444	16,556
Investment loss	250,000
Amortization of right to use asset	66,598
Amortization of Debt Discount		152	152	88,647
Changes in operating assets and liabilities:
Accounts Receivable	(282,746)	(102,382)	(1,532)	(20,354)
Prepaid Assets and other Current Assets	(100,100)	(70,194)	13,637	(90,763)
Inventory	16,650	(13,865)	(3,810)
Other Assets		(20,500)
Lease Liability	(55,102)
Accounts Payable	(2,557)	248	95,149	(98,213)
Accrued Liabilities and Other Liabilities	43,256	98,062	(18,791)	(293,521)
Net Cash provided by operating activities	324,565	231,315	273,386	171,670
Investing Activities:
Purchase of Fixed Assets			(15,006)
Cash paid for acquisition of Community Specialty Pharmacy, LLC, net of cash received			(250,273)
Purchase of equity method investment	(250,000)
Net cash Used in Investing activities	(250,000)		(265,279)
Financing Activities:
Proceeds from Convertible Note - Related Parties				180,000
Repayments of Short-Term Convertible Debt - Related Parties	(40,000)	(111,725)
Repayments of Promissory Note - Third Parties			(10,739)	(432,685)
Repayments of Short-Term Promissory Notes		(10,739)	(111,725)
Proceeds from exercise of Warrants	166			250
Proceeds from Issuance of Common Stock	2,455,000	300,000	800,000	250,000
Net Cash provided by financing activities	2,415,166	177,536	677,536	(2,435)
Net increase in Cash	2,489,731	408,851	685,643	169,235
Cash at Beginning	869,557	183,914	183,914	14,679
Cash at End	3,359,288	592,765	869,557	183,914
Supplemental Cash Flow Information
Cash Paid for Interest	40,705	40,028	36,970	71,210
Cash Paid for Income Taxes
Non-Cash Transactions
Common Stock Issued for Conversion of Note and Accrued Interest	211,983
ROU assets and operating lease obligations recognized	$ 847,441
Related party note payable and warrants issued for acquisition of Community Specialty Pharmacy, LLC			470,921
Reclass from accrued interest to short term convertible notes				16,500
Arrangement to move related party Accounts Payable to Notes Payable				$ 32,552

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended	12 Months Ended
Organization and Basis of Presentation	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION Trxade Group, Inc. (“ we our Trxade Company Trxade, Inc., operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products. Community Specialty Pharmacy, LLC, is an accredited independent retail pharmacy with a focus on specialty medications. The company operates with an innovative pharmacy model which offers home delivery services to patients thereby providing convenience. Alliance Pharma Solutions, LLC, has developed a same day Pharma delivery software – Delivmeds.com, and invested in SyncHealth MSO, LLC, a managed services organization during January 2019. Basis of Presentation In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2018 as reported in the Company’s Annual Report on Form 10-K have been omitted. Equity Investments The share of income (loss) of such entities is recorded as a single amount as share in equity income (loss) of investments. Dividends, if any, are recorded as a reduction of the investment. The equity investment was fully impaired at September 30, 2019. Income Per Common Share The following table sets forth the computation of basic and diluted Income per Share: For three months ended September 30, For nine months ended September 30, 2019 2018 2019 2018 Numerator: Net Income $ 27,565 $ 94,249 $ 210,775 $ 197,031 Numerator for basic and diluted EPS - income available to common Shareholders 27,565 $ 94,249 210,775 $ 197,031 Denominator: Denominator for basic EPS – Weighted average shares 34,489,969 32,083,629 34,370,522 32,083,629 Dilutive Effect of Warrants, Options and Convertible Debt 1,796,518 2,654,335 1,796,518 2,648,911 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 36,286,487 34,737,964 36,167,040 34,732,540 Basic and Diluted income per common share $ 0.00 $ 0.00 $ 0.01 $ 0.01 Recent Accounting Pronouncements Effective January 1, 2019, the Company adopted ASU No. 2016-02, Leases (Topic 842 ASU 2016-02 ROU Effective January 1, 2019, the Company adopted ASU No. 2018-07, Compensation – Stock Based Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ ASU 2018-7	NOTE 1 – ORGANIZATION Trxade Group, Inc. (“ we our Trxade Company Trxade, Inc. operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories and services. Integra Pharma Solutions, LLC is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products. Community Specialty Pharmacy, LLC is an accredited independent retail pharmacy with a focus on specialty medications. The company operates with an innovative pharmacy model which offers home delivery services to any patient thereby providing convenience. Alliance Pharma Solutions, LLC has developed same day Pharma delivery software – Delivmeds.com and invested in SyncHealth MSO, LLC, a managed services organization in January 2019. (See Note 13).

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“ GAAP The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America (“ GAAP Basis of Presentation – Historically, operations have been funded primarily through the sale of equity or debt securities and operating activities. In 2018, the Company renewed outstanding debt (See Note 3 and 4), raised capital (See Note 5) and had positive operating cash flow from operations. The Company has the ability to maintain the current level of spending or reduce expenditures to maintain operations if funding is not available. Use of Estimates – In preparing these financial statements, management is required to make estimates and assumptions that effect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Reclassification – Certain prior year amounts have been reclassified to conform to the current year presentation. Principle of Consolidation – The Company’s consolidated financial statements include the accounts of Trxade Group, Inc., Trxade, Inc., Integra Pharma Solutions, Inc., Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. All significant intercompany accounts and transactions have been eliminated. Cash and Cash Equivalents – Cash in bank accounts are at risk to the extent that they exceed U.S. Federal Deposit Insurance Corporation insured amounts. All investments purchased with a maturity of three months or less are cash equivalents. Cash and cash equivalents are available on demand and are generally within of FDIC insurance limits for 2018. Accounts Receivable – The Company’s receivables are from customers and are collected within 90 days. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. During the years ended December 31, 2018 and 2017, $2,271 of bad debt expense and $0 of recovery of bad debt was recognized, respectively. Inventory – Inventories are stated at the lower of cost or net realizable value. Cost is determined on a weighted average basis. On a quarterly basis, we analyze our inventory levels and no reserve is maintained as obsolete or expired inventories are written off. There is no reserve for inventory obsolescence during the periods presented. Beneficial Conversion Features – The intrinsic value of a beneficial conversion feature inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the date the note is due using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the beneficial conversion feature is measured by comparing the effective conversion price, after considering the relative value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion. Derivative financial instruments – The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes option pricing model, assuming maximum value, in accordance with ASC 815-15 “Derivative and Hedging” to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. Fair Value of Financial Instruments – The Company measures its financial assets and liabilities in accordance with the requirements of FASB ASC 820, “ Fair Value Measurements and Disclosures Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis. The carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term debt approximate fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates fair value because the debt is based on current rates at which the Company could borrow funds with similar maturities. Goodwill – The Company accounts for goodwill and intangible assets in accordance with ASC 350 “ Intangibles Goodwill and Other Revenue Recognition – In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 (Topic 606) “ Revenue from Contracts with Customers Trxade, Inc. provides an online website service, a buying and selling marketplace for licensed Pharmaceutical Wholesalers to sell products and services to licensed Pharmacies. The Company charges Suppliers a transaction fee, a percentage of the purchase price of the Prescription Drugs and other products sold through its website service. The fulfillment of confirmed orders, including delivery and shipment of Prescription Drugs and other products, is the responsibility of the Supplier and not of the Company. The Company holds no inventory and assumes no responsibility for the shipment or delivery of any products or services from our website. The Company considers itself an agent for this revenue stream and as such, reports revenue as net. Step One: Identify the contract with the customer – Trxade, Inc.’s Terms and Use Agreement is acknowledged between the Wholesaler and Trxade, Inc. which outlines the terms and conditions. The collection is probable based on the credit evaluation of the Wholesaler. Step Two: Identify the performance obligations in the contract – The Company provides to the Supplier access to the online website, uploading of catalogs of products and Dashboard access to review status of inventory posted and processed orders. The Agreement requires the supplier to provide a catalog of pharmaceuticals for posting on the platform, deliver the pharmaceuticals and upon shipment remit the stated platform fee. Step Three: Determine the transaction price – The Fee Agreement outlines the fee based on the type of product, generic, brand or non-drug. There are no discounts for volume of transactions or early payment of invoices. Step Four: Allocate the transaction price – The Fee Agreement outlines the fee. There is no difference between contract price and “ stand-alone selling price Integra Pharma Solutions, LLC is a licensed wholesaler and sells to licensed pharmacies brand, generic and non-drug products. The Company takes orders for products and creates invoices for each order and recognizes revenue at the time the Customer receives the product. Customer returns are not material. Step One: Identify the contract with the customer – The Company requires that an application and a credit card for payment is completed by the Customer prior to the first order. Each transaction is evidenced by an order form sent by the customer and an invoice for the product is sent by the Company. The collection is probable based on the application and credit card information provided prior to the first order. Step Two: Identify the performance obligations in the contract – Each order is distinct and evidenced by the shipping order and invoice. Step Three: Determine the transaction price – The consideration is variable if product is returned. The variability is determined based on the return policy of the product manufacturer. There are no sales or volume discounts. The transaction price is determined at the time of the order evidenced by the invoice. Step Four: Allocate the transaction price – There is no difference between contract price and “ stand-alone selling price Community Specialty Pharmacy, LLC is in the retail pharmacy business. The Company fills prescriptions for drugs written by a doctor and recognizes revenue at the time the patient confirms delivery of the prescription. Customer returns are not material. Step One: Identify the contract with the customer – The prescription is written by a doctor for a Customer and delivered to the Company. The prescription identifies the performance obligations in the contract. The Company fills the prescription and delivers to the Customer the prescription, fulfilling the contract. The collection is probable because there is confirmation that the customer has insurance for the reimbursement to the Company prior to filling of the prescription. Step Two: Identify the performance obligations in the contract – Each prescription is distinct to the Customer. Step Three: Determine the transaction price – The consideration is not variable. The transaction price is determined to be the price of the prescription at the time of delivery which considers the expected reimbursements from third party payors (e.g., pharmacy benefit managers, insurance companies and government agencies). Step Four: Allocate the transaction price – The price of the prescription invoiced represents the expected amount of reimbursement from third party payors. There is no difference between contract price and “ stand-alone selling price Cost of Goods Sold – The Company recognized cost of goods sold in 2018 from activities in Integra Pharma Solutions, LLC and Community Specialty Pharmacy, LLC, which were not active in 2017. Stock-Based Compensation – The Company accounts for stock-based compensation to non-employees in accordance with the provision of ASC 505, “ Equity Based Payments to Non-Employees ASC 505 The Company accounts for stock-based compensation to employees in accordance with ASC 718, “ Compensation-Stock Compensation Income Taxes – The Company accounts for income taxes utilizing ASC 740, “ Income Taxes Income (loss) Per Share – Basic net income (loss) per common share is computed by dividing net loss available to Common Stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed similar to basic net loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The treasury stock method and as if converted methods are used to determine the dilutive shares for our options and warrants and convertible notes, respectively. The following table sets forth the computation of basic and diluted income per common share for the years ended December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Numerator: Net Income $ 9,038 $ 288,983 Numerator for basic and diluted income available to common shareholders $ 9,038 $ 288,983 Denominator: Denominator for basic income per common share – Weighted average common shares outstanding 32,260,622 31,955,416 Dilutive effect of Common Stock Equivalents 2,697,880 2,130,835 Denominator for diluted income per common share – adjusted weighted average common shares outstanding 34,958,502 34,086,251 Basic and Diluted income per common share $ 0.00 $ 0.01 Concentration of Credit Risks and Major Customers - Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The Company places its cash and cash equivalents with financial institutions. Deposits are insured to Federal Deposit Insurance Corp limits. During the years ended December 31, 2018 and 2017, sales to two customers each represent greater than 10% of revenue. Recent Accounting Pronouncements – The Company has implemented all new relevant accounting pronouncements that are in effect through the date of these financial statements. The pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial position or results of operations. In February 2016, the FASB issued ASU 2016-02, Leases, which will amend current lease accounting to require lessees to recognize (i) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and (ii) a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 does not significantly change lease accounting requirements applicable to lessors; however, certain changes were made to align, where necessary, lessor accounting with the lessee accounting model. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the provisions of this ASU at January 1, 2019.

Short-Term Debt and Related Par

Short-Term Debt and Related Parties Debt	9 Months Ended	12 Months Ended
Short-Term Debt and Related Parties Debt	Sep. 30, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Short-Term Debt and Related Parties Debt	NOTE 2 – SHORT-TERM DEBT AND RELATED PARTIES DEBT Convertible Promissory Note In February 2019, convertible promissory notes issued in 2015 for $181,500 were amended to have a conversion price of $0.50 per share, and the principal and accrued interest totaling $211,983, were then converted into 423,966 common shares. As of September 30, 2019 and December 31, 2018, short-term convertible notes payable has a balance of $0 and $181,500, respectively, net of $0 unamortized debt discount. Related Party Convertible Promissory Note As of September 30, 2019, the $40,000 in convertible promissory notes due to Mr. Shilpa Patel, a relative of Mr. Prashant Patel, the Company’s President and director, was paid in full. As of September 30, 2019, a $100,000 convertible promissory note was due to Mr. Nitil Patel, the brother of Mr. Prashant Patel, the Company’s President and director. Simple interest of 10% is payable at the maturity date of the note. In July 2019, the note was extended to October 15, 2019, and the modification was not considered substantial. The note was converted in October 2019 into 200,000 shares of common stock. See NOTE 11 – SUBSEQUENT EVENTS. As of September 30, 2019, $122,552 and $100,000 in promissory notes were due to Mr. Prashant Patel and Mr. Suren Ajjarapu, the President and director, and Chief Executive Officer and Chairman, respectively. The notes are due on July 1, 2020 and each bear interest at the rate of 6% per annum. The notes were paid in full on October 8, 2019. See NOTE 11 – SUBSEQUENT EVENTS.	NOTE 3 – SHORT-TERM DEBT AND RELATED PARTIES DEBT Convertible Promissory Note Convertible promissory notes were issued in the aggregate amount of $200,000 in April and May 2015. The term of the notes was one year. Simple interest of 10% was payable at the maturity date of the note. Prior to maturity the notes may be converted for Common Stock at a conversion price of $1.50. The holders of the notes were granted warrants at one share of Common Stock for every $4.00 of the note principal amount, which totaled a warrant to purchase 50,000 shares of Common Stock. These warrants were issued at a strike price of $1.50 and an expiration date of five years from date of issuance. The Company used the Black-Scholes pricing model to estimate the fair value of the warrants issued along with convertible notes on the date of grant. The Company accounted for the relative fair value of the warrants issued and a total debt discount $53,546 was recorded. In April and May 2016, $50,000 of the $200,000 in convertible promissory notes (plus $5,000 in interest) was repaid. A one-year extension was executed on the remaining notes and the interest owed, totaling $15,000 became part of the adjusted principal of notes and the balance of $165,000 is due May 2017. In connection with the one-year extension of the maturity date of the outstanding notes, the holders of the notes were granted warrants at one Common Stock for $4.00 of the note amount and warrants to purchase 41,250 shares of Common Stock were issued at a strike price of $1.50 and an expiration date of five years from date of issuance. The amendment of the note was considered a debt extinguishment and a loss on extinguishment of debt was booked in the amount of $37,579. In April 2017, $165,000 in convertible promissory notes (plus $5,500 in interest) was amended. A two-year extension was executed on the remaining notes and the interest owed, totaling $16,500 became part of the adjusted principal of the notes and the balance of $181,500 is due May 2019. The conversion price was adjusted to $0.85 per share. In connection with the two-year extension of the maturity date of the outstanding notes, the holders of the notes were granted warrants to purchase 18,150 shares of Common Stock that was issued at a strike price of $0.65 and an expiration date of five years from date of issuance. The amendment of the note was considered a debt extinguishment and a loss on extinguishment of debt was booked in the amount of $11,512. The Company evaluated the embedded conversion feature within the above convertible notes under ASC 815-15 and ASC 815-40 and determined that the embedded conversion feature does not meet the definition of a derivative liability. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the convertible note payable and the conversion was not beneficial and a total debt discount from the issued warrants of $53,546 was recorded in 2015 and $0 as of the date of the debt modification. During 2017, debt discount of $0 was amortized. As of December 31, 2018 and 2017, short-tern convertible note has a balance of $181,500 and $0 respectively, net of $0 unamortized debt discount. Promissory Note In May 2016, a promissory note that was issued in May 2015 was renewed in the face amount of $250,000 and the term was extended an additional year. The note has an original issuance discount of $45,000 and this amount was paid in cash at the renewal. During 2016, a debt discount of $45,000 was amortized. As of December 31, 2016, the promissory note has a balance of $250,000 with an unamortized debt discount of $15,000. During 2017 the debt discount of $15,000 was fully amortized and the balance of $250,000 was paid. In October 2016, a promissory note was issued in the face amount of $47,000. The term of the note was one year. Payments are made daily and $3,917 of principal was paid in 2016. At December 31, 2016 the balance was $43,083. In 2017 $43,083 of principal was paid and at December 31, 2017 the balance was $0. In September 2016, a promissory note was issued for $189,000. The term of the note is 494 days. The debt discount was $39,000 thus the initial net proceeds were $150,000. At December 31, 2016, $139,602 was classified as short term with a discount of $25,306 and $10,739 was classified as long term with a discount of $152. Payments are made each weekday in the amount of $537. In 2017, $139,602 was paid off by cash and debt discount of $25,306 was amortized. As of December 31, 2017, short term promissory notes have a balance of $10,739, net of $152 unamortized debt discount. In 2018, $10,739 was paid off by cash and the debt discount of $152 was amortized. As of December 31, 2018, short term promissory notes have a balance of $0, net of $0 unamortized debt discount. Related Party Convertible Promissory Notes In August 2016, $40,000 in promissory notes were issued to Mr. Shilpa Patel, a relative of Mr. Prashant Patel. The term of the note was one year. Simple interest of 10% is payable at the maturity date of the note. Prior to maturity the note may be converted for Common Stock at a conversion price of $1.50. In August 2017, $40,000 in convertible promissory notes was amended. A one-year extension was executed to August 2018. In connection with the one-year extension of the maturity date of the outstanding notes, the holder of the notes was granted warrants to purchase 10,000 shares of Common Stock that was issued at a strike price of $0.80 and an expiration date of five years from date of issuance. The amendment of the note was considered a debt extinguishment and a loss on extinguishment of debt was booked in the amount of $5,044. In August 2018, $40,000 in convertible promissory notes was amended. A one-year extension was executed to August 2019. In connection with the one-year extension of the maturity date of the outstanding notes, the holder of the notes was granted warrants to purchase 10,000 shares of Common Stock that was issued at a strike price of $0.50 and an expiration date of five years from date of issuance. The amendment of the note was considered a debt extinguishment and a loss on extinguishment of debt was booked in the amount of $7,444. The Company evaluated the embedded conversion feature within the above convertible notes under ASC 815-15 and ASC 815-40 and determined that the embedded conversion feature does not meet the definition of a derivative liability. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the convertible note payable and $0 was recorded as of the grant date. In September and October 2016, convertible promissory notes were issued in the aggregate amount of $211,725 to a related party, Mr. Nitil Patel, the brother of Mr. Prashant Patel. The term of the notes was one year. Simple interest of 10% is payable at the maturity date of the notes. Prior to maturity the notes may be converted for Common Stock at a conversion price of $0.62. In connection with the notes, the holders of the notes were granted warrants to purchase 52,861 shares of Common Stock. These warrants were issued at a strike price of $0.62 and an expiration date of five years from date of issuance. The Company evaluated the embedded conversion feature within the above convertible notes under ASC 815-15 and ASC 815-40 and determined that the embedded conversion feature does not meet the definition of a derivative liability. Then the Company evaluated the conversion feature for a beneficial conversion feature at inception. The Company accounted for the intrinsic value of a Beneficial Conversion Feature inherent to the convertible note payable and the beneficial feature was not beneficial and a total debt discount of $65,390 due to the warrants was recorded as of the grant date. In April 2017, a $61,725 related party note was renewed for a one-year extension at the same interest rate of 10%, due April 2018. In April 2018, $61,725 was paid in cash for full payment. In September 2017, a $150,000 related party note was renewed for a six-month extension at the same interest rate of 10%, due in February 2018. In February 2018, $100,000 of the related party note was extended to July 2018 and then renewed for a year extension at the same interest rate of 10%, due July 2019. The remaining $50,000 was paid in cash in February 2018. During 2017, the remaining debt discount of $48,341 was fully amortized. As of December 31, 2017, the short-term related party convertible notes had a principal balance of $251,725, net of an unamortized debt discount of $0. As of December 31, 2018, the short-term related party convertible notes had a principal balance of $140,000, net of an unamortized debt discount of $0. Related Party Promissory Note In November 2016, Mr. Prashant Patel loaned the Company $10,000. The term of the loan is 90 days and is at zero percent interest. The balance at December 31, 2016 was $10,000. In February 2017, $7,280 of accounts payable to Mr. Patel was added to the loan. The term of the loan was extended for 90 days and is at a zero interest rate. An additional $25,272 of accounts payable was added to the loan in the second quarter and the balance of $42,552 was converted to long-term debt in July 2017 and will mature in July 2020. (See Note 4).

Long Term Debt

Long Term Debt	12 Months Ended
Long Term Debt	Dec. 31, 2018
Debt Disclosure [Abstract]
Long Term Debt	NOTE 4 – LONG TERM DEBT In 2017, there are $181,500 in convertible promissory notes due in May 2019 as described in Note 3. Related Party Promissory Notes In June 2017, the Company satisfied an outstanding promissory note, dated May 8, 2016, as amended, in the principal amount of $250,000 (the “ NPR Note Lender In connection with the foregoing satisfaction of the NPR Note above, the Company received funds in June 2017 and entered into a promissory note agreement on July 1, 2017, whereby the Company borrowed $100,000 and $80,000 from Sansur Associates, LLC, a limited liability company controlled by Mr. Ajjarapu, and Mr. Patel, respectively (the “ Promissory Notes otes is three years and they each bear interest at 6%, which is payable annually. The note due to Mr. Patel is $ In October 2018 in connection with the acquisition of Community Specialty Pharmacy, LLC a $300,000 promissory note was issued to Nikul Panchal, accruing interest a simple interest of 10%, interest payable annually, and principal payable at maturity on October 15, 2021. At December 31, 2018 and 2017, total related party long term debt was $522,552 and $222,552, respectively. Future maturities of long-term debt in the next five years are as follows: Due in 2020 $ 222,552 Due in 2021 $ 300,000 Due in 2022 $ - Due in 2023 $ - Total Debt $ 522,552

Long Term Debt - Related Partie

Long Term Debt - Related Parties	9 Months Ended
Long Term Debt - Related Parties	Sep. 30, 2019
Long Term Debt - Related Parties
Long Term Debt - Related Parties	NOTE 3 – LONG TERM DEBT – RELATED PARTIES In October 2018, in connection with the acquisition of Community Specialty Pharmacy, LLC, a $300,000 promissory note was issued to Nikul Panchal, a non-executive officer of the Company, accruing simple interest at the rate of 10% per annum, payable annually, and having a maturity date in October 2021. In October 2019, $75,000 of the note was converted into 150,000 common shares. See NOTE 11 –SUBSEQUENT EVENTS.

Shareholders' Equity

Shareholders' Equity	9 Months Ended	12 Months Ended
Shareholders' Equity	Sep. 30, 2019	Dec. 31, 2018
Equity [Abstract]
Shareholders' Equity	NOTE 4 – SHAREHOLDERS’ EQUITY In July 2018, under a Private Offer Memorandum, 300,000 shares of common stock were sold for $300,000 in cash. The common stock was sold at $1.00 per share. In connection with this common stock offering, warrants to purchase 161,538 shares of common stock were issued with a strike price of $0.01 and an expiration date of five years. In February 2019, convertible promissory notes issued in 2015 in the amount of $181,500, were amended to include a conversion price of $0.50 per share, and the principal and accrued interest totaling $211,983 was then converted into 423,966 common shares. In February 2019, warrants to purchase 16,666 shares of common stock issued in 2014 with an exercise price of $0.01 per share were exercised for $166 in cash and the Company issued 16,666 common shares. In April and May 2019, options to purchase 505,000 shares of common stock were granted with exercise prices of between $0.41 and $0.44 per share, and a term of 10 years from the grant date. The options vest over a period of four to five years. On July 10, 2019, the Company entered into a securities Purchase Agreement with a certain accredited investor with respect to the private placement of 2,000,000 shares of its common stock at a purchase price of $0.50 per share, for gross proceeds of $1,000,000. This transaction closed on July 30, 2019. On September 1, 2019, the Company granted Flacane Advisors, Inc., a company controlled by Gary Augusta, a member of the Board of Directors of the Company, warrants to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.01 per share. Based on the agreement, warrants to purchase 150,000 shares vest on April 1, 2020 and warrants to purchase 150,000 shares vest on April 1, 2021. The warrants have a term of 5 years. On September 30, 2019, the Company entered into Securities Purchase Agreements with certain accredited investors with respect to the private placement of 2,910,000 shares of common stock at a purchase price of $0.50 per share, for gross proceeds of $1,455,000. Subscribers included Bedford Falls Capital, which is controlled by Gary Augusta, our former director (1,000,000 shares); Nitesh Patel, who is the cousin of Prashant Patel, our director and President (40,000 shares); and Shilpa Patel, who is the spouse of Nitesh Patel, the brother of Prashant Patel, our director and President (20,000 shares).	NOTE 5 – STOCKHOLDERS’ EQUITY 2017 In January 2017, under a Private Offer Memorandum, 250,000 shares of Common Stock were issued for $250,000 cash. The Common Stock was sold at $1.00 per share. In connection with this Common Stock offering, warrants to purchase 87,500 shares of Common Stock were issued with a strike price of $0.01 and an expiration date of five years. In February 2017, 25,000 shares were issued when warrants were exercised at $0.01 grant price for $250. In March 2017, 50,000 shares were issued for services performed for the Company and valued at fair value of $12,500. 2018 In July 2018, under a Private Offer Memorandum, 300,000 shares of Common Stock were issued for $300,000 cash. The Common Stock was sold at $1.00 per share. In connection with this Common Stock offering, warrants to purchase 161,538 shares of Common Stock were issued with a strike price of $0.01 and an expiration date of five years. In November 2018, under a Private Offer Memorandum, 1,000,000 shares of Common Stock were issued for $500,000 cash. The Common Stock was sold at $0.50 per share.

Warrants

Warrants	9 Months Ended	12 Months Ended
Warrants	Sep. 30, 2019	Dec. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Warrants	NOTE 5 - WARRANTS For the nine-month period ended September 30, 2019, warrants to purchase 16,666 shares of common stock were exercised, 300,000 were granted and none forfeited. See NOTE 4 – SHAREHOLDERS’ EQUITY. The Company uses the Black-Scholes pricing model to estimate the fair value of stock-based awards on the date of the grant. The following table summarizes the assumptions used to estimate the fair value of the warrants granted during the nine months ended September 30, 2019. 2019 Expected dividend yield 0 % Weighted-average expected volatility 217 % Weighted-average risk-free interest rate 2.75 % Expected life of warrants 5 years The total fair value of warrants issued was $269,719. The compensation cost related to the warrants was $26,363 for the nine-months ended September 30, 2019. The Company’s outstanding and exercisable warrants as of September 30, 2019 are presented below: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2018 2,880,141 $ 0.08 3.74 $ 782,385 Warrants granted 300,000 $ 0.01 - - Warrants forfeited - - - - Warrants exercised (16,666 ) $ 0.01 - - Warrants Outstanding as of September 30, 2019 3,163,475 $ 0.08 3.02 $ 3,574,954	NOTE 6 - WARRANTS In 2017, 87,500 warrants were issued related to common shares sold for cash (See Note 5). Likewise, 28,150 were issued for renewal of convertible debt (see Note 3) and 25,000 warrants were exercised. No warrants were forfeited in 2017. In 2018, 161,538 warrants were issued related to common shares sold for cash (see Note 5), 10,000 were issued for renewal of convertible debt (see Note 3), 405,507 were issued related to the acquisition of Community Specialty Pharmacy, LLC, none were exercised and 435,000 were forfeited. The following table summarizes the assumptions used to estimate the fair value of warrants granted during the years ended December 31, 2018 and 2017: 2018 2017 Expected dividend yield 0 % 0 % Weighted-average expected volatility 231-632 % 200 % Weighted-average risk-free interest rate 2.55-2.75 % 1.81-1.84 % Expected life of warrants 5-8 years 5 years The Company’s outstanding and exercisable warrants as of December 31, 2018 and 2017 are presented below: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2016 2,647,446 $ 0.24 4.24 $ 930,751 Warrants granted 115,650 $ 0.18 5.0 - Warrants forfeited - - - - Warrants exercised (25,000 ) $ 0.01 - - Warrants Outstanding as of December 31, 2017 2,738,096 $ 0.24 3.28 $ 937,567 Warrants granted 577,045 $ 0.02 7.11 Warrants forfeited (435,000 ) - - - Warrants exercised - - - - Warrants Outstanding as of December 31, 2018 2,880,141 $ 0.08 3.74 $ 782,385

Options

Options	9 Months Ended	12 Months Ended
Options	Sep. 30, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Options	NOTE 6 – OPTIONS The Company maintains a stock option plan under which certain employees are awarded option grants based on a combination of performance and tenure. The stock option plan provides for the grant of up to 2,000,000 shares. All options may be exercised for a period of up to four and a half years following the grant date, after which they expire. Options are vested up to 5 years from the grant date. For the nine-month period ended September 30, 2019, options to purchase 505,000 shares of common stock were issued, 25,800 were forfeited and 35,700 expired, due to employee resignations. The Company uses the Black-Sholes option pricing model to estimate the fair value of stock-based awards on the date of the grant. The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the nine months ended September 30, 2019. 2019 Expected dividend yield 0 % Weighted-average expected volatility 209-250 % Weighted-average risk-free interest rate 2.08-2.55 % Expected life of options 5-7 years Total compensation cost related to stock options was $141,594 and $133,048 for the nine-months ended September 30, 2019 and 2018, respectively. The following table represents stock option activity for the nine-month period ended September 30, 2019: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2018 1,732,846 $ 1.19 6.98 $ - Options Exercisable as of December 31, 2018 1,107,259 $ 0.96 5.91 Options granted 505,000 $ 0.43 - - Options forfeited 25,800 $ 0.92 - - Options expired 35,700 $ 0.60 - - Options Outstanding as of September 30, 2019 2,176,346 $ 0.73 7.01 $ 1,303,547 Options Exercisable as of September 30, 2019 1,204,521 $ 0.89 5.69 $ 537,356	NOTE 7 - OPTIONS The Company maintains a stock option plan under which certain employees and management are awarded option grants based on a combination of performance and tenure. All options may be exercised for a period up to four and ½ years following the grant date, after which they expire. Options are vested up to 5 years from the grant date. The Board has authorized the use of 2,000,000 shares for option grants. Stock options were granted during 2018 and 2017 to employees totaling, 560,400 and 263,846, respectively. These options vest over a period of 4 to 5 years, are granted with an exercise price of between $0.41 and $1.02 per share and have a term of 10 years. The last options expire April 2028. Under the Black-Scholes option price model, fair value of the options granted in 2018 and 2017 were $278,358 and $169,100, respectively. In April 2017, 253,846 options were granted with an exercise price of $0.65 and a term of 10 years from the grant date. The options vest over a period of one and four years. In April 2017, four option grants, totaling 650,000 options, were amended to extend the exercise terms to 10 years from the date of grant. Incremental option expense recognized as a result of the amendment amounted to $69,611. In April 2018, 560,400 options were granted with an exercise price of $0.50 and a term of 10 years from the grant date. The options vest over a period of four to five years. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock-based awards on the date of grant. The following table summarizes the assumptions used to estimate the fair value of stock options granted during the years ended December 31, 2018 and 2017: 2018 2017 Expected dividend yield 0 % 0 % Weighted-average expected volatility 192-265 % 200 % Weighted-average risk-free interest rate 2.08-2.73 % 1.92 % Expected life of warrants 4-5 years 4.74 -7.50 years Total compensation cost related to stock options was $169,828 and $267,835 for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, there was $192,007 of unrecognized compensation costs related to stock options, which is expected to be recognized over a weighted average period of 6.98 years. The following table represents stock option activity for the two years ended December 31, 2018: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2016 1,044,500 $ 0.92 3.38 $ - Options Exercisable as of December 31, 2016 584,000 $ 1.05 3.02 Options granted 263,846 0.64 9.05 - Options forfeited (35,000 ) 1.02 8.25 - Options expired (75,000 ) 1.13 4.54 - Options Outstanding as of December 31, 2017 1,197,846 $ 0.97 6.96 $ - Options Exercisable as of December 31, 2017 781,300 $ 1.02 6.30 $ - Options granted 560,400 0.50 9.26 Options forfeited (25,400 ) 0.46 9.06 Options expired - - - - Options Outstanding as of December 31, 2018 1,732,846 $ 1.19 6.98 $ - Options Exercisable as of December 31, 2018 1,107,259 $ 0.96 5.91 $ -

Leases

Leases	9 Months Ended
Leases	Sep. 30, 2019
Leases [Abstract]
Leases	NOTE 7 – LEASES The Company elected the practical expedient under ASU 2018-11 “ Leases: Targeted Improvements Lease 1 Lease 2 Initial Lease Term December 2017 to December 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of Right to use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 % The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of September 30, 2019 Amounts due within twelve months of September 30 2019 $ 159,538 2020 164,299 2021 169,223 2022 174,320 2023 179,552 Thereafter 259,858 Total minimum lease payments 1,106,790 Less: effect of discounting (314,451 ) Present value of future minimum lease payments 792,339 Less: current obligations under leases 84,050 Long-term lease obligations $ 708,289 For the three-months and nine-months ended September 30, 2019, amortization of assets was $22,658 and $66,598, respectively. For the three-months and nine-months ended September 30, 2019, amortization of liabilities was $18,826 and $55,102, respectively.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 8 – INCOME TAXES On December 22, 2017 H.R. 1, originally known as the Tax Cuts and Jobs Act, (the “ Tax Act Federal Tax Rate The statutory tax rate is the percentage imposed by law; the effective tax rate is the percentage of income actually paid by a company after taking into account tax deductions, exemptions, credits and operating loss carry forwards. At December 31, 2018 and 2017 deferred tax assets consist of the following: December 31, 2018 December 31, 2017 Federal loss carry forwards $ 922,850 $ 963,833 Less: valuation allowance (922,850 ) (963,833 ) $ - $ - The Company has established a valuation allowance equal to the full amount of the deferred tax asset primarily due to uncertainty in the utilization of the net operating loss carry forwards. The estimated net operating loss carry forwards of approximately $4,400,000 will be available based on the new carryover rules in section 172(a) passed with the Tax Cuts and Jobs Acts.

Related Parties

Related Parties	12 Months Ended
Related Parties	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Parties	NOTE 9 – RELATED PARTIES In January 2017, Mr. Ajjarapu and Mr. Patel suspended their executive salaries of $165,000 and $125,000, for a period of five and six months, respectively. In January 2018, Mr. Ajjarapu and Mr. Patel’s executive salaries were amended to $200,000 and $150,000, respectively. All of our executives are at-will employees or consultants. Each of Messrs. Ajjarapu and Patel are parties to an at-will executive employment agreement. The Company owed management wages to Mr. Prashant Patel at December 31, 2018 of $0 and December 31, 2017 of $62,500, respectively. In October 2018 in connection with the acquisition of Community Specialty Pharmacy, LLC, a $300,000 promissory note was issued to Nikul Panchal, accruing interest at a simple interest of 10%, interest payable annually, and principal payable at maturity on October 15, 2021.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 10 – COMMITMENTS AND CONTINGENCIES The Company leases two premises in Land O’ Lakes, Florida under an operating lease that expires in 2021 and in Tampa, Florida under an operating lease that expires in 2023. Future minimum rental payments under these non-cancelable operating leases as of December 31, 2018 are: 2019 $ 156,024 2020 $ 160,709 2021 $ 165,506 2022 $ 49,080 2023 $ 41,934 Total $ 573,253

Segment Reporting

Segment Reporting	9 Months Ended	12 Months Ended
Segment Reporting	Sep. 30, 2019	Dec. 31, 2018
Segment Reporting [Abstract]
Segment Reporting	NOTE 8 – SEGMENT REPORTING The Company classifies its business interests into reportable segments which are Trxade, Community Specialty and Integra. Nine Months Ended September 30, 2019 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Unallocated Total Revenue $ 3,335,050 $ 1,412,449 $ 992,862 $ - $ 5,740,361 Segment Assets $ 1,561,760 $ 315,681 411,161 $ 3,565,921 $ 5,854,523 Segment Profit/Loss $ 1,748,896 $ (75,955 ) $ (122,144 ) $ (1,340,022 ) $ 210,775 The Company had no reportable segments for the nine months ended September 30, 2018. See NOTE 9 – BUSINESS COMBINATION.	NOTE 11 – SEGMENT REPORTING The Company classifies its business interests into reportable segments which are Trxade, Inc., Community Specialty Pharmacy, LLC, and Other. Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Our chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment. Year Ended December 31, 2018 Trxade, Inc. Community Specialty Pharmacy, LLC Other Revenue $ 3,407,822 $ 395,418 $ 28,538 Gross Profit $ 3,407,822 $ (34,971 ) $ 9,878 Segment Assets $ 822,412 $ 112,123 $ 1,293,052 Segment Profit/Loss $ 1,371,615 $ (116,588 ) $ (1,245,989 ) The Company had no reportable segments in 2017. See Note 12.

Business Combination

Business Combination	9 Months Ended	12 Months Ended
Business Combination	Sep. 30, 2019	Dec. 31, 2018
Business Combinations [Abstract]
Business Combination	NOTE 9 – BUSINESS COMBINATION On October 15, 2018, Trxade Group, Inc. (“ Company CSP Seller The Company recorded the acquisition under ASC 805 “ Business Combination the fair value of the warrants issued calculated under the Black-Scholes calculation at $170,291. Purchase Price Allocation Purchase Price $ 770,291 Cash (49,728 ) Accounts Receivable (114,899 ) Inventory (76,156 ) Prepaid (3,000 ) Accounts Payable 199,312 Accrued Expenses 153 Goodwill $ 725,973 The accompanying unaudited pro forma statements of operations present the accounts of Trxade and CSP for the nine- months ended September 30, 2018, assuming the acquisition occurred on January 1, 2018. 2018 Summary Statement of Operations Trxade CSP Combined Revenue $ 2,538,082 $ 1,985,620 $ 4,523,702 Net Income $ 197,031 $ 97,371 $ 294,402 Net Income per common share – basic $ 0.01 $ 0.01 Net Income per common share - diluted $ 0.01 $ 0.01 Weighted average common shares - basic 32,083,629 32,083,629 Weighted average common shares - diluted 34,732,540 34,732,540 The accompanying unaudited pro forma statements of operations present the accounts of Trxade and CSP for the three-months ended September 30, 2018, assuming the acquisition occurred on January 1, 2018. 2018 Summary Statement of Operations Trxade CSP Combined Revenue $ 847,471 $ 662,503 $ 1,509,974 Net Income $ 94,249 $ 109,556 $ 203,805 Net Income per common share – basic $ 0.00 $ 0.01 Net Income per common share - diluted $ 0.00 $ 0.01 Weighted average common shares - basic 32,083,629 32,083,629 Weighted average common shares - diluted 34,737,964 34,737,964	NOTE 12 – BUSINESS COMBINATION On October 15, 2018, the Company entered into and consummated the purchase of 100% of the equity interests of Community Specialty Pharmacy, LLC, a Florida limited liability company, (“CSP”), pursuant to the terms and conditions of the Membership Interest Purchase Agreement, entered into by and among the Company as the buyer, and CSP, and Nikul Panchal, the equity owner of CSP (collectively, the “Seller”). The purchase price for the 100% equity interest in CSP was $300,000 in cash, a promissory note issued by the Company of $300,000 (see Note 4), and warrants to purchase 405,507 shares of the Common Stock of the Company which vested at the acquisition date, are exercisable for eight (8) years from the issuance date at a strike price of $0.01 per share, and subject to exercise restrictions which lapse over a period of three (3) years. The Company recorded the acquisition under the guidance of ASC 805 “ Business Combinations the fair value for the warrants issued calculated under the Black-Scholes calculation at $170,291. Purchase Price Allocation Purchase Price $ 770,291 Cash (49,728 ) Accounts Receivable (114,899 ) Inventory (76,156 ) Prepaid (3,000 ) Accounts Payable 199,312 Accrued Expenses 153 Goodwill $ 725,973 The accompanying unaudited pro forma combined statements of operations presents the accounts of Trxade and CSP for the years ended December 31, 2018 and 2017, respectively, assuming the acquisition occurred on January 1, 2017. 2018 Summary Statement of Operations Trxade CSP Combined Revenue $ 3,436,360 $ 2,387,636 $ 5,823,996 Net Income (Loss) $ 125,626 $ (6,723 ) $ 118,903 Net Income per common share – basic $ 0.00 $ 0.00 Net Income per common share - diluted $ 0.00 $ 0.00 Weighted average common shares - basic 32,260,622 32,260,622 Weighted average common shares - diluted 34,958,502 34,958,502 2017 Summary Statement of Operations Trxade CSP Combined Revenue $ 2,931,280 $ 2,633,914 $ 5,565,194 Net Income (Loss) $ 288,983 $ (63,132 ) $ 225,851 Net Income per common share – basic $ 0.01 $ 0.01 Net Income per common share - diluted $ 0.01 $ 0.01 Weighted average common shares - basic 31,955,416 31,955,416 Weighted average common shares - diluted 34,086,251 34,086,251

Equity Method Investment

Equity Method Investment	9 Months Ended
Equity Method Investment	Sep. 30, 2019
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment	NOTE 10 – EQUITY METHOD INVESTMENT In January 2019, the Company, through its wholly-owned subsidiary Alliance Pharma Solution, LLC (“Alliance”), entered into a transaction to form SyncHealth MSO, LLC (“SyncHealth”). SyncHealth is owned by PanOptic Health, LLC (“PanOptic”) and Alliance. Alliance contributed $250,000 for the acquisition of a 49% equity interest in SyncHealth and the option to acquire the remaining ownership from PanOptic shareholders. Prior to March 31, 2019, $210,000 was paid with the remaining $40,000 paid in April 2019. Pursuant to the operating agreement, PanOptic owns 70% of SyncHealth and Alliance owns 30%; however, pursuant to the Letter Agreement, PanOptic will transfer to Alliance an additional 6% of SyncHealth’s membership units on May 1, 2019, an additional 6% on August 1, 2019 and an additional 7% on November 1, 2019, and at Alliance’s option, the 51% balance on January 31, 2020, upon transfer of between 2,273,329 and 14,776,638 shares of Company common stock based on 2019 Gross Revenue Quotas. As of September 30, 2019, we have not realized any income from the technology and presently we are in discussions to dissolve this relationship. The remaining investment is impaired and written down to $0. For the three-months and nine-months ended September 30, 2019, the Company recorded its equity share in the losses of SyncHealth amounting to $162,178 and $250,000, respectively.

Subsequent Event

Subsequent Event	9 Months Ended	12 Months Ended
Subsequent Event	Sep. 30, 2019	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Event	NOTE 11 – SUBSEQUENT EVENT On October 8, 2019, $122,552 and $100,000 in promissory notes due to Mr. Prashant Patel and Mr. Suren Ajjarapu, the President and director, and Chief Executive Officer and Chairman, respectively, were paid in full. The notes were due July 1, 2020. In October 2019, the Company converted $175,000 of principal owed under various outstanding promissory notes into 350,000 shares common stock of the Company at $0.50 per share. On October 23, 2019 (the “ Closing Date Seller Member Assets Closing Shares Milestone Shares APA Shares 1. 240,000 shares upon the placement, by the Company, of 40 in-store wellness kiosks, utilizing the Tele Meds Platform, on or before the first anniversary of the Closing Date; 2. 205,000 shares upon placement, by the Company, of 70 in-store wellness kiosks utilizing the Tele Meds Platform, on or before the first anniversary of the Closing Date; and 3. 205,000 shares upon placement, by the Company, of 100 in-store wellness kiosks utilizing the Tele Meds Platform on or before the first anniversary of the Closing Date. The Asset Purchase Agreement includes a three year non-compete requirement, prohibiting the Seller and the Member from competing against the Assets, customary representations and indemnification obligations, subject to a $25,000 minimal claim amount and certain limitations on liability disclosed in the Asset Purchase Agreement. The Asset Purchase Agreement also requires the Company to fund up to $600,000 in connection with the remote hub installation, marketing and IT, subject to certain milestones set forth in the Asset Purchase Agreement (the “ Funding Obligation Subsequent to the acquisition, the Company determined that the Assets were not usable and wrote off the value of the Assets amounting to approximately $359,000.	NOTE 13 – SUBSEQUENT EVENTS In January 2019, Trxade Group, Inc. through its wholly-owned subsidiary Alliance Pharma Solution, LLC (“ Alliance SyncHealth PanOptic In February 2019, convertible promissory notes issued in 2015 for $150,000 were amended to reduce the conversion price from $0.85 to $0.50 and the remaining principal and accrued interest total of $211,983 were converted to 423,966 common shares. In February 2019, 16,666 of warrants issued in 2014 at $0.01 were converted for $166 to 16,666 of common shares.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Policies)	9 Months Ended	12 Months Ended
Organization and Basis of Presentation (Policies)	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2018 as reported in the Company’s Annual Report on Form 10-K have been omitted.	Basis of Presentation – Historically, operations have been funded primarily through the sale of equity or debt securities and operating activities. In 2018, the Company renewed outstanding debt (See Note 3 and 4), raised capital (See Note 5) and had positive operating cash flow from operations. The Company has the ability to maintain the current level of spending or reduce expenditures to maintain operations if funding is not available.
Equity Investments	Equity Investments The share of income (loss) of such entities is recorded as a single amount as share in equity income (loss) of investments. Dividends, if any, are recorded as a reduction of the investment. The equity investment was fully impaired at September 30, 2019.
Income Per Common Share	Income Per Common Share The following table sets forth the computation of basic and diluted Income per Share: For three months ended September 30, For nine months ended September 30, 2019 2018 2019 2018 Numerator: Net Income $ 27,565 $ 94,249 $ 210,775 $ 197,031 Numerator for basic and diluted EPS - income available to common Shareholders 27,565 $ 94,249 210,775 $ 197,031 Denominator: Denominator for basic EPS – Weighted average shares 34,489,969 32,083,629 34,370,522 32,083,629 Dilutive Effect of Warrants, Options and Convertible Debt 1,796,518 2,654,335 1,796,518 2,648,911 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 36,286,487 34,737,964 36,167,040 34,732,540 Basic and Diluted income per common share $ 0.00 $ 0.00 $ 0.01 $ 0.01	Income (loss) Per Share – Basic net income (loss) per common share is computed by dividing net loss available to Common Stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed similar to basic net loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The treasury stock method and as if converted methods are used to determine the dilutive shares for our options and warrants and convertible notes, respectively. The following table sets forth the computation of basic and diluted income per common share for the years ended December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Numerator: Net Income $ 9,038 $ 288,983 Numerator for basic and diluted income available to common shareholders $ 9,038 $ 288,983 Denominator: Denominator for basic income per common share – Weighted average common shares outstanding 32,260,622 31,955,416 Dilutive effect of Common Stock Equivalents 2,697,880 2,130,835 Denominator for diluted income per common share – adjusted weighted average common shares outstanding 34,958,502 34,086,251 Basic and Diluted income per common share $ 0.00 $ 0.01
Recent Accounting Pronouncements	Recent Accounting Pronouncements Effective January 1, 2019, the Company adopted ASU No. 2016-02, Leases (Topic 842 ASU 2016-02 ROU Effective January 1, 2019, the Company adopted ASU No. 2018-07, Compensation – Stock Based Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ ASU 2018-7	Recent Accounting Pronouncements – The Company has implemented all new relevant accounting pronouncements that are in effect through the date of these financial statements. The pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial position or results of operations. In February 2016, the FASB issued ASU 2016-02, Leases, which will amend current lease accounting to require lessees to recognize (i) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and (ii) a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 does not significantly change lease accounting requirements applicable to lessors; however, certain changes were made to align, where necessary, lessor accounting with the lessee accounting model. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the provisions of this ASU at January 1, 2019.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2018 as reported in the Company’s Annual Report on Form 10-K have been omitted.	Basis of Presentation – Historically, operations have been funded primarily through the sale of equity or debt securities and operating activities. In 2018, the Company renewed outstanding debt (See Note 3 and 4), raised capital (See Note 5) and had positive operating cash flow from operations. The Company has the ability to maintain the current level of spending or reduce expenditures to maintain operations if funding is not available.
Use of Estimates		Use of Estimates – In preparing these financial statements, management is required to make estimates and assumptions that effect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Reclassification		Reclassification – Certain prior year amounts have been reclassified to conform to the current year presentation.
Principle of Consolidation		Principle of Consolidation – The Company’s consolidated financial statements include the accounts of Trxade Group, Inc., Trxade, Inc., Integra Pharma Solutions, Inc., Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents		Cash and Cash Equivalents – Cash in bank accounts are at risk to the extent that they exceed U.S. Federal Deposit Insurance Corporation insured amounts. All investments purchased with a maturity of three months or less are cash equivalents. Cash and cash equivalents are available on demand and are generally within of FDIC insurance limits for 2018.
Accounts Receivable		Accounts Receivable – The Company’s receivables are from customers and are collected within 90 days. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. During the years ended December 31, 2018 and 2017, $2,271 of bad debt expense and $0 of recovery of bad debt was recognized, respectively.
Inventory		Inventory – Inventories are stated at the lower of cost or net realizable value. Cost is determined on a weighted average basis. On a quarterly basis, we analyze our inventory levels and no reserve is maintained as obsolete or expired inventories are written off. There is no reserve for inventory obsolescence during the periods presented.
Beneficial Conversion Features		Beneficial Conversion Features – The intrinsic value of a beneficial conversion feature inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the date the note is due using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the beneficial conversion feature is measured by comparing the effective conversion price, after considering the relative value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion.
Derivative Financial Instruments		Derivative financial instruments – The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes option pricing model, assuming maximum value, in accordance with ASC 815-15 “Derivative and Hedging” to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
Fair Value of Financial Instruments		Fair Value of Financial Instruments – The Company measures its financial assets and liabilities in accordance with the requirements of FASB ASC 820, “ Fair Value Measurements and Disclosures Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis. The carrying amounts of cash, accounts receivable, accounts payable, accrued liabilities and short-term debt approximate fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates fair value because the debt is based on current rates at which the Company could borrow funds with similar maturities.
Goodwill		Goodwill – The Company accounts for goodwill and intangible assets in accordance with ASC 350 “ Intangibles Goodwill and Other
Revenue Recognition		Revenue Recognition – In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09 (Topic 606) “ Revenue from Contracts with Customers Trxade, Inc. provides an online website service, a buying and selling marketplace for licensed Pharmaceutical Wholesalers to sell products and services to licensed Pharmacies. The Company charges Suppliers a transaction fee, a percentage of the purchase price of the Prescription Drugs and other products sold through its website service. The fulfillment of confirmed orders, including delivery and shipment of Prescription Drugs and other products, is the responsibility of the Supplier and not of the Company. The Company holds no inventory and assumes no responsibility for the shipment or delivery of any products or services from our website. The Company considers itself an agent for this revenue stream and as such, reports revenue as net. Step One: Identify the contract with the customer – Trxade, Inc.’s Terms and Use Agreement is acknowledged between the Wholesaler and Trxade, Inc. which outlines the terms and conditions. The collection is probable based on the credit evaluation of the Wholesaler. Step Two: Identify the performance obligations in the contract – The Company provides to the Supplier access to the online website, uploading of catalogs of products and Dashboard access to review status of inventory posted and processed orders. The Agreement requires the supplier to provide a catalog of pharmaceuticals for posting on the platform, deliver the pharmaceuticals and upon shipment remit the stated platform fee. Step Three: Determine the transaction price – The Fee Agreement outlines the fee based on the type of product, generic, brand or non-drug. There are no discounts for volume of transactions or early payment of invoices. Step Four: Allocate the transaction price – The Fee Agreement outlines the fee. There is no difference between contract price and “ stand-alone selling price Integra Pharma Solutions, LLC is a licensed wholesaler and sells to licensed pharmacies brand, generic and non-drug products. The Company takes orders for products and creates invoices for each order and recognizes revenue at the time the Customer receives the product. Customer returns are not material. Step One: Identify the contract with the customer – The Company requires that an application and a credit card for payment is completed by the Customer prior to the first order. Each transaction is evidenced by an order form sent by the customer and an invoice for the product is sent by the Company. The collection is probable based on the application and credit card information provided prior to the first order. Step Two: Identify the performance obligations in the contract – Each order is distinct and evidenced by the shipping order and invoice. Step Three: Determine the transaction price – The consideration is variable if product is returned. The variability is determined based on the return policy of the product manufacturer. There are no sales or volume discounts. The transaction price is determined at the time of the order evidenced by the invoice. Step Four: Allocate the transaction price – There is no difference between contract price and “ stand-alone selling price Community Specialty Pharmacy, LLC is in the retail pharmacy business. The Company fills prescriptions for drugs written by a doctor and recognizes revenue at the time the patient confirms delivery of the prescription. Customer returns are not material. Step One: Identify the contract with the customer – The prescription is written by a doctor for a Customer and delivered to the Company. The prescription identifies the performance obligations in the contract. The Company fills the prescription and delivers to the Customer the prescription, fulfilling the contract. The collection is probable because there is confirmation that the customer has insurance for the reimbursement to the Company prior to filling of the prescription. Step Two: Identify the performance obligations in the contract – Each prescription is distinct to the Customer. Step Three: Determine the transaction price – The consideration is not variable. The transaction price is determined to be the price of the prescription at the time of delivery which considers the expected reimbursements from third party payors (e.g., pharmacy benefit managers, insurance companies and government agencies). Step Four: Allocate the transaction price – The price of the prescription invoiced represents the expected amount of reimbursement from third party payors. There is no difference between contract price and “ stand-alone selling price
Cost of Goods Sold		Cost of Goods Sold – The Company recognized cost of goods sold in 2018 from activities in Integra Pharma Solutions, LLC and Community Specialty Pharmacy, LLC, which were not active in 2017.
Stock-based Compensation		Stock-Based Compensation – The Company accounts for stock-based compensation to non-employees in accordance with the provision of ASC 505, “ Equity Based Payments to Non-Employees ASC 505 The Company accounts for stock-based compensation to employees in accordance with ASC 718, “ Compensation-Stock Compensation
Income Taxes		Income Taxes – The Company accounts for income taxes utilizing ASC 740, “ Income Taxes
Income (loss) Per Share	Income Per Common Share The following table sets forth the computation of basic and diluted Income per Share: For three months ended September 30, For nine months ended September 30, 2019 2018 2019 2018 Numerator: Net Income $ 27,565 $ 94,249 $ 210,775 $ 197,031 Numerator for basic and diluted EPS - income available to common Shareholders 27,565 $ 94,249 210,775 $ 197,031 Denominator: Denominator for basic EPS – Weighted average shares 34,489,969 32,083,629 34,370,522 32,083,629 Dilutive Effect of Warrants, Options and Convertible Debt 1,796,518 2,654,335 1,796,518 2,648,911 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 36,286,487 34,737,964 36,167,040 34,732,540 Basic and Diluted income per common share $ 0.00 $ 0.00 $ 0.01 $ 0.01	Income (loss) Per Share – Basic net income (loss) per common share is computed by dividing net loss available to Common Stockholders by the weighted average number of common shares outstanding. Diluted net loss per common share is computed similar to basic net loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The treasury stock method and as if converted methods are used to determine the dilutive shares for our options and warrants and convertible notes, respectively. The following table sets forth the computation of basic and diluted income per common share for the years ended December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Numerator: Net Income $ 9,038 $ 288,983 Numerator for basic and diluted income available to common shareholders $ 9,038 $ 288,983 Denominator: Denominator for basic income per common share – Weighted average common shares outstanding 32,260,622 31,955,416 Dilutive effect of Common Stock Equivalents 2,697,880 2,130,835 Denominator for diluted income per common share – adjusted weighted average common shares outstanding 34,958,502 34,086,251 Basic and Diluted income per common share $ 0.00 $ 0.01
Concentration of Credit Risks and Major Customers		Concentration of Credit Risks and Major Customers - Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The Company places its cash and cash equivalents with financial institutions. Deposits are insured to Federal Deposit Insurance Corp limits. During the years ended December 31, 2018 and 2017, sales to two customers each represent greater than 10% of revenue.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Effective January 1, 2019, the Company adopted ASU No. 2016-02, Leases (Topic 842 ASU 2016-02 ROU Effective January 1, 2019, the Company adopted ASU No. 2018-07, Compensation – Stock Based Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ ASU 2018-7	Recent Accounting Pronouncements – The Company has implemented all new relevant accounting pronouncements that are in effect through the date of these financial statements. The pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial position or results of operations. In February 2016, the FASB issued ASU 2016-02, Leases, which will amend current lease accounting to require lessees to recognize (i) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and (ii) a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 does not significantly change lease accounting requirements applicable to lessors; however, certain changes were made to align, where necessary, lessor accounting with the lessee accounting model. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted the provisions of this ASU at January 1, 2019.

Organization and Basis of Pre_3

Organization and Basis of Presentation (Tables)	9 Months Ended	12 Months Ended
Organization and Basis of Presentation (Tables)	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted Income per Share: For three months ended September 30, For nine months ended September 30, 2019 2018 2019 2018 Numerator: Net Income $ 27,565 $ 94,249 $ 210,775 $ 197,031 Numerator for basic and diluted EPS - income available to common Shareholders 27,565 $ 94,249 210,775 $ 197,031 Denominator: Denominator for basic EPS – Weighted average shares 34,489,969 32,083,629 34,370,522 32,083,629 Dilutive Effect of Warrants, Options and Convertible Debt 1,796,518 2,654,335 1,796,518 2,648,911 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 36,286,487 34,737,964 36,167,040 34,732,540 Basic and Diluted income per common share $ 0.00 $ 0.00 $ 0.01 $ 0.01	The following table sets forth the computation of basic and diluted income per common share for the years ended December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Numerator: Net Income $ 9,038 $ 288,983 Numerator for basic and diluted income available to common shareholders $ 9,038 $ 288,983 Denominator: Denominator for basic income per common share – Weighted average common shares outstanding 32,260,622 31,955,416 Dilutive effect of Common Stock Equivalents 2,697,880 2,130,835 Denominator for diluted income per common share – adjusted weighted average common shares outstanding 34,958,502 34,086,251 Basic and Diluted income per common share $ 0.00 $ 0.01

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted Income per Share: For three months ended September 30, For nine months ended September 30, 2019 2018 2019 2018 Numerator: Net Income $ 27,565 $ 94,249 $ 210,775 $ 197,031 Numerator for basic and diluted EPS - income available to common Shareholders 27,565 $ 94,249 210,775 $ 197,031 Denominator: Denominator for basic EPS – Weighted average shares 34,489,969 32,083,629 34,370,522 32,083,629 Dilutive Effect of Warrants, Options and Convertible Debt 1,796,518 2,654,335 1,796,518 2,648,911 Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions 36,286,487 34,737,964 36,167,040 34,732,540 Basic and Diluted income per common share $ 0.00 $ 0.00 $ 0.01 $ 0.01	The following table sets forth the computation of basic and diluted income per common share for the years ended December 31, 2018 and 2017: December 31, 2018 December 31, 2017 Numerator: Net Income $ 9,038 $ 288,983 Numerator for basic and diluted income available to common shareholders $ 9,038 $ 288,983 Denominator: Denominator for basic income per common share – Weighted average common shares outstanding 32,260,622 31,955,416 Dilutive effect of Common Stock Equivalents 2,697,880 2,130,835 Denominator for diluted income per common share – adjusted weighted average common shares outstanding 34,958,502 34,086,251 Basic and Diluted income per common share $ 0.00 $ 0.01

Long Term Debt (Tables)

Long Term Debt (Tables)	12 Months Ended
Long Term Debt (Tables)	Dec. 31, 2018
Debt Disclosure [Abstract]
Schedule of Future Maturities of Long-term Debt	Future maturities of long-term debt in the next five years are as follows: Due in 2020 $ 222,552 Due in 2021 $ 300,000 Due in 2022 $ - Due in 2023 $ - Total Debt $ 522,552

Warrants (Tables)

Warrants (Tables)	9 Months Ended	12 Months Ended
Warrants (Tables)	Sep. 30, 2019	Dec. 31, 2018
Warrants and Rights Note Disclosure [Abstract]
Summary of Assumptions Used to Estimate Fair Value of Warrants Granted	The following table summarizes the assumptions used to estimate the fair value of the warrants granted during the nine months ended September 30, 2019. 2019 Expected dividend yield 0 % Weighted-average expected volatility 217 % Weighted-average risk-free interest rate 2.75 % Expected life of warrants 5 years	The following table summarizes the assumptions used to estimate the fair value of warrants granted during the years ended December 31, 2018 and 2017: 2018 2017 Expected dividend yield 0 % 0 % Weighted-average expected volatility 231-632 % 200 % Weighted-average risk-free interest rate 2.55-2.75 % 1.81-1.84 % Expected life of warrants 5-8 years 5 years
Schedule of Outstanding and Exercisable Warrants	The Company’s outstanding and exercisable warrants as of September 30, 2019 are presented below: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2018 2,880,141 $ 0.08 3.74 $ 782,385 Warrants granted 300,000 $ 0.01 - - Warrants forfeited - - - - Warrants exercised (16,666 ) $ 0.01 - - Warrants Outstanding as of September 30, 2019 3,163,475 $ 0.08 3.02 $ 3,574,954	The Company’s outstanding and exercisable warrants as of December 31, 2018 and 2017 are presented below: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Warrants Outstanding as of December 31, 2016 2,647,446 $ 0.24 4.24 $ 930,751 Warrants granted 115,650 $ 0.18 5.0 - Warrants forfeited - - - - Warrants exercised (25,000 ) $ 0.01 - - Warrants Outstanding as of December 31, 2017 2,738,096 $ 0.24 3.28 $ 937,567 Warrants granted 577,045 $ 0.02 7.11 Warrants forfeited (435,000 ) - - - Warrants exercised - - - - Warrants Outstanding as of December 31, 2018 2,880,141 $ 0.08 3.74 $ 782,385

Options (Tables)

Options (Tables)	9 Months Ended	12 Months Ended
Options (Tables)	Sep. 30, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Schedule of Estimate Fair Value of Stock Options	The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the nine months ended September 30, 2019. 2019 Expected dividend yield 0 % Weighted-average expected volatility 209-250 % Weighted-average risk-free interest rate 2.08-2.55 % Expected life of options 5-7 years	The following table summarizes the assumptions used to estimate the fair value of stock options granted during the years ended December 31, 2018 and 2017: 2018 2017 Expected dividend yield 0 % 0 % Weighted-average expected volatility 192-265 % 200 % Weighted-average risk-free interest rate 2.08-2.73 % 1.92 % Expected life of warrants 4-5 years 4.74 -7.50 years
Schedule of Stock Option Activity	The following table represents stock option activity for the nine-month period ended September 30, 2019: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2018 1,732,846 $ 1.19 6.98 $ - Options Exercisable as of December 31, 2018 1,107,259 $ 0.96 5.91 Options granted 505,000 $ 0.43 - - Options forfeited 25,800 $ 0.92 - - Options expired 35,700 $ 0.60 - - Options Outstanding as of September 30, 2019 2,176,346 $ 0.73 7.01 $ 1,303,547 Options Exercisable as of September 30, 2019 1,204,521 $ 0.89 5.69 $ 537,356	The following table represents stock option activity for the two years ended December 31, 2018: Number Outstanding Weighted Average Exercise Price Contractual Life in Years Intrinsic Value Options Outstanding as of December 31, 2016 1,044,500 $ 0.92 3.38 $ - Options Exercisable as of December 31, 2016 584,000 $ 1.05 3.02 Options granted 263,846 0.64 9.05 - Options forfeited (35,000 ) 1.02 8.25 - Options expired (75,000 ) 1.13 4.54 - Options Outstanding as of December 31, 2017 1,197,846 $ 0.97 6.96 $ - Options Exercisable as of December 31, 2017 781,300 $ 1.02 6.30 $ - Options granted 560,400 0.50 9.26 Options forfeited (25,400 ) 0.46 9.06 Options expired - - - - Options Outstanding as of December 31, 2018 1,732,846 $ 1.19 6.98 $ - Options Exercisable as of December 31, 2018 1,107,259 $ 0.96 5.91 $ -

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Sep. 30, 2019
Leases [Abstract]
Schedule of Operating Leases	Lease 1 Lease 2 Initial Lease Term December 2017 to December 2021 November 2018 to November 2023 Renewal Term January 2021 to December 2024 November 2023 to November 2028 Initial Recognition of Right to use assets at January 1, 2019 $ 534,140 $ 313,301 Incremental Borrowing Rate 10 % 10 %
Schedule of Future Minimum Payments for Operating Lease Liabilities	The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of September 30, 2019 Amounts due within twelve months of September 30 2019 $ 159,538 2020 164,299 2021 169,223 2022 174,320 2023 179,552 Thereafter 259,858 Total minimum lease payments 1,106,790 Less: effect of discounting (314,451 ) Present value of future minimum lease payments 792,339 Less: current obligations under leases 84,050 Long-term lease obligations $ 708,289

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	At December 31, 2018 and 2017 deferred tax assets consist of the following: December 31, 2018 December 31, 2017 Federal loss carry forwards $ 922,850 $ 963,833 Less: valuation allowance (922,850 ) (963,833 ) $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments Under Non-cancelable Operating Leases	The Company leases two premises in Land O’ Lakes, Florida under an operating lease that expires in 2021 and in Tampa, Florida under an operating lease that expires in 2023. Future minimum rental payments under these non-cancelable operating leases as of December 31, 2018 are: 2019 $ 156,024 2020 $ 160,709 2021 $ 165,506 2022 $ 49,080 2023 $ 41,934 Total $ 573,253

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended	12 Months Ended
Segment Reporting (Tables)	Sep. 30, 2019	Dec. 31, 2018
Segment Reporting [Abstract]
Schedule of Business Interests Into Reportable Segments	The Company classifies its business interests into reportable segments which are Trxade, Community Specialty and Integra. Nine Months Ended September 30, 2019 Trxade, Inc. Community Specialty Pharmacy, LLC Integra Pharma, LLC Unallocated Total Revenue $ 3,335,050 $ 1,412,449 $ 992,862 $ - $ 5,740,361 Segment Assets $ 1,561,760 $ 315,681 411,161 $ 3,565,921 $ 5,854,523 Segment Profit/Loss $ 1,748,896 $ (75,955 ) $ (122,144 ) $ (1,340,022 ) $ 210,775	Year Ended December 31, 2018 Trxade, Inc. Community Specialty Pharmacy, LLC Other Revenue $ 3,407,822 $ 395,418 $ 28,538 Gross Profit $ 3,407,822 $ (34,971 ) $ 9,878 Segment Assets $ 822,412 $ 112,123 $ 1,293,052 Segment Profit/Loss $ 1,371,615 $ (116,588 ) $ (1,245,989 )

Business Combination (Tables)

Business Combination (Tables)	9 Months Ended	12 Months Ended
Business Combination (Tables)	Sep. 30, 2019	Dec. 31, 2018
Business Combinations [Abstract]
Schedule of Assets Acquired and Liabilities Assumed	Purchase Price Allocation Purchase Price $ 770,291 Cash (49,728 ) Accounts Receivable (114,899 ) Inventory (76,156 ) Prepaid (3,000 ) Accounts Payable 199,312 Accrued Expenses 153 Goodwill $ 725,973	Purchase Price Allocation Purchase Price $ 770,291 Cash (49,728 ) Accounts Receivable (114,899 ) Inventory (76,156 ) Prepaid (3,000 ) Accounts Payable 199,312 Accrued Expenses 153 Goodwill $ 725,973
Schedule of Unaudited Pro Forma Statements of Operations	The accompanying unaudited pro forma statements of operations present the accounts of Trxade and CSP for the nine- months ended September 30, 2018, assuming the acquisition occurred on January 1, 2018. 2018 Summary Statement of Operations Trxade CSP Combined Revenue $ 2,538,082 $ 1,985,620 $ 4,523,702 Net Income $ 197,031 $ 97,371 $ 294,402 Net Income per common share – basic $ 0.01 $ 0.01 Net Income per common share - diluted $ 0.01 $ 0.01 Weighted average common shares - basic 32,083,629 32,083,629 Weighted average common shares - diluted 34,732,540 34,732,540 The accompanying unaudited pro forma statements of operations present the accounts of Trxade and CSP for the three-months ended September 30, 2018, assuming the acquisition occurred on January 1, 2018. 2018 Summary Statement of Operations Trxade CSP Combined Revenue $ 847,471 $ 662,503 $ 1,509,974 Net Income $ 94,249 $ 109,556 $ 203,805 Net Income per common share – basic $ 0.00 $ 0.01 Net Income per common share - diluted $ 0.00 $ 0.01 Weighted average common shares - basic 32,083,629 32,083,629 Weighted average common shares - diluted 34,737,964 34,737,964	The accompanying unaudited pro forma combined statements of operations presents the accounts of Trxade and CSP for the years ended December 31, 2018 and 2017, respectively, assuming the acquisition occurred on January 1, 2017. 2018 Summary Statement of Operations Trxade CSP Combined Revenue $ 3,436,360 $ 2,387,636 $ 5,823,996 Net Income (Loss) $ 125,626 $ (6,723 ) $ 118,903 Net Income per common share – basic $ 0.00 $ 0.00 Net Income per common share - diluted $ 0.00 $ 0.00 Weighted average common shares - basic 32,260,622 32,260,622 Weighted average common shares - diluted 34,958,502 34,958,502 2017 Summary Statement of Operations Trxade CSP Combined Revenue $ 2,931,280 $ 2,633,914 $ 5,565,194 Net Income (Loss) $ 288,983 $ (63,132 ) $ 225,851 Net Income per common share – basic $ 0.01 $ 0.01 Net Income per common share - diluted $ 0.01 $ 0.01 Weighted average common shares - basic 31,955,416 31,955,416 Weighted average common shares - diluted 34,086,251 34,086,251

Organization and Basis of Pre_4

Organization and Basis of Presentation (Details Narrative)	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage	100.00%	100.00%

Organization (Details Narrative

Organization (Details Narrative) (10-K)	Sep. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage	100.00%	100.00%

Organization and Basis of Pre_5

Organization and Basis of Presentation - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income	$ 27,565	$ 57,981	$ 125,229	$ 94,249	$ 20,513	$ 82,269	$ 210,775	$ 197,031	$ 9,038	$ 288,983
Numerator for basic and diluted EPS - income available to common Shareholders	$ 27,565			$ 94,249			$ 210,775	$ 197,031	$ 9,038	$ 288,983
Denominator for basic EPS - Weighted average shares	34,489,969			32,083,629			34,370,522	32,083,629	32,260,622	31,955,416
Dilutive Effect of Warrants, Options and Convertible Debt	1,796,518			2,654,335			1,796,518	2,648,911	2,697,880	2,130,835
Denominator for diluted EPS - adjusted Weighted average shares and assumed Conversions	36,286,487			34,737,964			36,167,040	34,732,540	34,958,502	34,086,251
Basic and Diluted income per common share	$ 0			$ 0			$ 0.01	$ 0.01	$ 0	$ 0.01

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) (10-K) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Bad debt expense	$ 6,084	$ 2,271	$ 2,271
Recovery of bad debt			$ 0	$ 0
Valuation allowance percentage			100.00%
Two Customers [Member]
Concentration risk, percentage			10.00%	10.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details) (10-K) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Net Income	$ 27,565	$ 57,981	$ 125,229	$ 94,249	$ 20,513	$ 82,269	$ 210,775	$ 197,031	$ 9,038	$ 288,983
Numerator for basic and diluted income available to common shareholders	$ 27,565			$ 94,249			$ 210,775	$ 197,031	$ 9,038	$ 288,983
Denominator for basic income per common share - Weighted average common shares outstanding	34,489,969			32,083,629			34,370,522	32,083,629	32,260,622	31,955,416
Dilutive effect of Common Stock Equivalents	1,796,518			2,654,335			1,796,518	2,648,911	2,697,880	2,130,835
Denominator for diluted income per common share - adjusted weighted average common shares outstanding	36,286,487			34,737,964			36,167,040	34,732,540	34,958,502	34,086,251
Basic and Diluted income per common share	$ 0			$ 0			$ 0.01	$ 0.01	$ 0	$ 0.01

Short-term Debt and Related P_2

Short-term Debt and Related Parties Debt (Details Narrative) - USD ($)

Oct. 08, 2019

Oct. 31, 2019

Jul. 31, 2019

Feb. 28, 2019

Feb. 28, 2018

Sep. 30, 2017

Jul. 31, 2017

Apr. 30, 2017

Feb. 28, 2017

May 31, 2016

Apr. 30, 2016

Sep. 30, 2019

Dec. 31, 2017

Dec. 31, 2018

Nov. 30, 2016

Oct. 31, 2016

Sep. 30, 2016

Aug. 31, 2016

May 31, 2015

Apr. 30, 2015

Short-term Debt [Line Items]

Convertible promissory notes

$ 181,500

Short term convertible notes payable

$ 181,500

Debt instrument maturity date

May 31,
2019

Subsequent Event [Member]

Short-term Debt [Line Items]

Debt instrument conversion price per share

$ 0.50

Debt principal and accrued interest, amount

$ 175,000

Debt instrument conversion shares

350,000

423,966

Mr. Prashant Patel [Member] | Subsequent Event [Member]

Short-term Debt [Line Items]

Debt instrument maturity date

Jul. 1,
2020

Mr. Suren Ajjarapul [Member] | Subsequent Event [Member]

Short-term Debt [Line Items]

Debt instrument maturity date

Jul. 1,
2020

Convertible Promissory Note [Member]

Short-term Debt [Line Items]

Convertible promissory notes

$ 181,500

$ 165,000

$ 200,000

Debt instrument conversion price per share

$ 0.50

$ 0.85

$ 1.50

Debt principal and accrued interest, amount

$ 211,983

Debt instrument conversion shares

423,966

Short term convertible notes payable

$ 0

181,500

Debt discount unamortized

$ 53,546

Interest rate

10.00%

Debt instrument maturity date

May 31,
2019

May 31,
2017

Related Party Convertible Promissory Note [Member]

Short-term Debt [Line Items]

Short term convertible notes payable

251,725

Debt discount unamortized

$ 0

$ 65,390

Interest rate

10.00%

Debt instrument maturity date

Jul. 31,
2019

Feb. 28,
2018

Apr. 30,
2018

Related Party Convertible Promissory Note [Member] | Mr. Shilpa Patel [Member]

Short-term Debt [Line Items]

Convertible promissory notes

40,000

Debt instrument conversion price per share

$ 1.50

Interest rate

10.00%

Related Party Convertible Promissory Note [Member] | Mr. Nitil Patel [Member]

Short-term Debt [Line Items]

Convertible promissory notes

$ 100,000

Debt instrument conversion price per share

$ 0.62

Interest rate

10.00%

Related Party Convertible Promissory Note [Member] | Mr. Nitil Patel [Member] | Subsequent Event [Member]

Short-term Debt [Line Items]

Debt instrument conversion shares

200,000

Related Party Convertible Promissory Note [Member] | Mr. Nitil Patel [Member] | Extended Maturity [Member]

Short-term Debt [Line Items]

Debt instrument maturity date

Oct. 15,
2019

Related Party Convertible Promissory Note [Member] | Mr. Prashant Patel [Member]

Short-term Debt [Line Items]

Convertible promissory notes

$ 122,552

Debt principal and accrued interest, amount

$ 42,552

Interest rate

0.00%

6.00%

0.00%

Debt instrument maturity date

Jul. 31,
2020

Jul. 1,
2020

Related Party Convertible Promissory Note [Member] | Mr. Suren Ajjarapul [Member]

Short-term Debt [Line Items]

Convertible promissory notes

$ 100,000

Interest rate

6.00%

Debt instrument maturity date

Jul. 1,
2020

Short-term Debt and Related P_3

Short-term Debt and Related Parties Debt (Details Narrative) (10-K) - USD ($)	1 Months Ended																	3 Months Ended		9 Months Ended		10 Months Ended	12 Months Ended
	Feb. 28, 2019	Aug. 31, 2018	Apr. 30, 2018	Feb. 28, 2018	Sep. 30, 2017	Aug. 31, 2017	Jul. 31, 2017	Apr. 30, 2017	Feb. 28, 2017	Nov. 30, 2016	Oct. 31, 2016	Sep. 30, 2016	Aug. 31, 2016	May 31, 2016	Apr. 30, 2016	May 31, 2015	Apr. 30, 2015	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Oct. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2018	Dec. 31, 2015
Convertible promissory notes																								$ 181,500
Warrant purchased from common stock																							161,538	87,500
Warrant strike price	$ 0.01								$ 0.01
Debt instrument maturity date																								May 31, 2019
Loss on extinguishment of debt																			$ (7,444)		$ (7,444)		$ (7,444)	$ (16,556)
Amortized debt																					$ 152		152	88,647
Short term convertible notes payable																							181,500
Long term promissory debt																							522,552
Mr. Prashant Patel [Member]
Due to related parties																							0	62,500
Warrant [Member]
Debt discount																											$ 53,546
Debt modification amount																											$ 0
Convertible Promissory Note [Member]
Convertible promissory notes	$ 181,500							$ 165,000						$ 200,000	$ 200,000	$ 200,000	$ 200,000
Debt notes term								2 years								1 year	1 year
Interest rate																10.00%	10.00%
Conversion price per share	$ 0.50							$ 0.85								$ 1.50	$ 1.50
Granted warrants														1	1	1	1
Shares issued price per shares														$ 4	$ 4	$ 4	$ 4
Warrant purchased from common stock								18,150						41,250	41,250	50,000	50,000
Warrant strike price								$ 0.65						$ 1.50	$ 1.50	$ 1.50	$ 1.50
Warrants term								5 years						5 years	5 years	5 years	5 years
Debt discount																$ 53,546	$ 53,546	0		0			0	0
Payment for promissory note														$ 50,000	$ 50,000
Interest expenses debt								$ 5,500						$ 5,000	$ 5,000
Debt instrument maturity, description								A two-year extension was executed on the remaining notes						A one-year extension was executed on the remaining notes	A one-year extension was executed on the remaining notes
Interest owed part of adjusted principal amount								$ 16,500						$ 15,000	$ 15,000
Debt instrument face amount								$ 181,500						$ 165,000	$ 165,000
Debt instrument maturity date								May 31, 2019						May 31, 2017	May 31, 2017
Loss on extinguishment of debt								$ 11,512						$ 37,579	$ 37,579
Amortized debt																								0
Short term convertible notes payable																		0		0			181,500	0
Debt instrument conversion amount	$ 211,983
Promissory Note [Member]
Debt notes term												494 days										1 year
Debt discount												$ 39,000		45,000											$ 15,000
Payment for promissory note																								250,000
Debt instrument face amount											$ 47,000	189,000		$ 250,000								$ 47,000			250,000
Amortized debt																								15,000	45,000
Principal payments																						$ 3,917
Proceeds from promissory note												$ 150,000
Promissory Note One [Member]
Payment for promissory note																								43,083
Debt instrument face amount																								0	43,083
Promissory Note Two [Member]
Short term convertible notes payable																									139,602
Principal payments																									537
Debt discount, current																									25,306
Long term promissory debt																									10,739
Debt discount non current																									152
Short Term Promissory Notes [Member]
Debt discount																							0	152
Payment for promissory note																								139,602
Amortized debt																								25,306
Short term convertible notes payable																							0	10,739
Promissory Notes [Member]
Payment for promissory note																							10,739
Amortized debt																							152
Related Party Convertible Promissory Note [Member]
Debt notes term				1 year	6 months			1 year
Interest rate				10.00%	10.00%			10.00%
Warrant purchased from common stock		10,000				10,000
Warrant strike price		$ 0.50				$ 0.80
Warrants term		5 years				5 years
Debt discount																							65,390	0
Payment for promissory note				$ 50,000
Debt instrument maturity, description		A one-year extension was executed to August 2019.				A one-year extension was executed to August 2018.
Debt instrument face amount		$ 40,000				$ 40,000
Debt instrument maturity date				Jul. 31, 2019	Feb. 28, 2018			Apr. 30, 2018
Loss on extinguishment of debt		$ 7,444				$ 5,044
Amortized debt																								48,341
Short term convertible notes payable																								$ 251,725
Debt instrument beneficial conversion features																							0
Due to related parties				$ 100,000	$ 150,000			$ 61,725
Related Party Convertible Promissory Note [Member] \| Mr. Shilpa Patel [Member]
Convertible promissory notes																		40,000		40,000
Debt notes term													1 year
Interest rate													10.00%
Conversion price per share													$ 1.50
Debt instrument face amount													$ 40,000
Related Party Convertible Promissory Note [Member] \| Mr. Nitil Patel [Member]
Convertible promissory notes																		$ 100,000		$ 100,000
Debt notes term											1 year	1 year
Interest rate											10.00%	10.00%						10.00%		10.00%		10.00%
Conversion price per share											$ 0.62	$ 0.62										$ 0.62
Warrant purchased from common stock											52,861	52,861										52,861
Warrant strike price											$ 0.62	$ 0.62										$ 0.62
Warrants term											5 years	5 years										5 years
Debt instrument face amount											$ 211,725	$ 211,725										$ 211,725
Related Party Convertible Promissory Note [Member] \| Mr. Prashant Patel [Member]
Convertible promissory notes																		$ 122,552		$ 122,552
Debt notes term									90 days	90 days
Interest rate									0.00%	0.00%								6.00%		6.00%
Debt instrument maturity date									Jul. 31, 2020											Jul. 1, 2020
Loan payable										$ 10,000															$ 10,000
Accounts payable									$ 7,280																	$ 25,272
Debt instrument conversion amount							$ 42,552
Related Party Convertible Promissory Note [Member]
Payment for promissory note			$ 61,725
Short-term Related Party Convertible Notes [Member]
Debt discount																							0
Short term convertible notes payable																							$ 140,000

Long Term Debt - Related Part_2

Long Term Debt - Related Parties (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Oct. 31, 2019	Feb. 28, 2019	Oct. 31, 2018	Dec. 31, 2017	Sep. 30, 2019	Dec. 31, 2018
Debt instrument maturity date				May 31, 2019
Long term debt related party				$ 222,552	$ 300,000	$ 522,552
Subsequent Event [Member]
Debt instrument conversion amount	$ 175,000
Debt instrument conversion shares	350,000	423,966
Related Party Promissory Note [Member] \| Community Specialty Pharmacy, LLC [Member] \| Nikul Panchal [Member]
Proceeds from issuance of promissory note			$ 300,000
Interest rate			10.00%
Debt instrument maturity date			Oct. 31, 2021
Related Party Promissory Note [Member] \| Community Specialty Pharmacy, LLC [Member] \| Nikul Panchal [Member] \| Subsequent Event [Member]
Debt instrument conversion amount	$ 75,000
Debt instrument conversion shares	150,000

Long Term Debt (Details Narrati

Long Term Debt (Details Narrative) (10-K) - USD ($)	1 Months Ended			10 Months Ended	12 Months Ended
Long Term Debt (Details Narrative) (10-K) - USD ($)	Oct. 31, 2018	Jun. 30, 2017	Sep. 30, 2016	Oct. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2019	Dec. 31, 2016	May 31, 2016
Convertible promissory notes						$ 181,500
Debt instrument maturity date						May 31, 2019
Credit card obligation					$ 25,272
Long term debt related party					522,552	$ 222,552	$ 300,000
Mr. Prashant Patel [Member]
Due to related parties					0	$ 62,500
Related Party Promissory Note [Member] \| Mr. Prashant Patel [Member]
Due to related parties					122,552
Related Party Promissory Note [Member] \| NPR Investment Group, LLC [Member]
Debt instrument face amount		$ 250,000			80,000
Related Party Promissory Note [Member] \| Sansur Associates, LLC [Member]
Debt instrument term		3 years
Interest rate		6.00%
Related Party Promissory Note [Member] \| Sansur Associates, LLC [Member] \| Mr. Suren Ajjarapu [Member]
Short term promissory note		$ 100,000
Related Party Promissory Note [Member] \| Sansur Associates, LLC [Member] \| Mr. Prashant Patel [Member]
Short term promissory note		$ 80,000
Related Party Promissory Note [Member] \| Specialty Pharmacy, LLC [Member] \| Nikul Panchal [Member]
Debt instrument maturity date	Oct. 15, 2021
Interest rate	10.00%
Proceeds from issuance of promissory note	$ 300,000
Promissory Note [Member]
Debt instrument face amount			$ 189,000	$ 47,000				$ 250,000	$ 250,000
Debt instrument term			494 days	1 year
Proceeds from issuance of promissory note			$ 150,000
Promissory Note [Member] \| Related Party Promissory Note [Member]
Debt instrument face amount					$ 17,280

Long Term Debt - Schedule of Fu

Long Term Debt - Schedule of Future Maturities of Long-term Debt (Details) (10-K)	Dec. 31, 2018USD ($)
Debt Disclosure [Abstract]
Due in 2020	$ 222,552
Due in 2021	300,000
Due in 2022
Due in 2023
Total Debt	$ 522,552

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	Sep. 30, 2019	Jul. 10, 2019	May 31, 2019	Apr. 30, 2019	Feb. 28, 2019	Jul. 31, 2018	Apr. 30, 2018	Apr. 30, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Aug. 28, 2019	Feb. 28, 2017	May 31, 2016	Apr. 30, 2016	May 31, 2015	Apr. 30, 2015
Class of Stock [Line Items]
Warrants to purchase common stock					16,666							25,000
Warrant exercise price					$ 0.01									$ 0.01
Convertible promissory notes												$ 181,500
Number of warrants exercised for cash					$ 166
Number of common shares issued for warrants exercised					16,666
Number of options, granted			505,000	505,000			560,400	253,846	505,000		560,400	263,846
Exercise price of options granted									$ 0.43		$ 0.50	$ 0.64
Option term			10 years	10 years					6 years 11 months 23 days		6 years 11 months 15 days	3 years 4 months 17 days
Proceeds from issuance of common stock									$ 2,455,000	$ 300,000	$ 800,000	$ 250,000
Gary Augusta [Member]
Class of Stock [Line Items]
Warrants to purchase common stock													300,000
Warrant exercise price													$ 0.01
Gary Augusta [Member] \| Vest on April 1, 2020 [Member]
Class of Stock [Line Items]
Warrants to purchase common stock													150,000
Gary Augusta [Member] \| Vest on April 1, 2021 [Member]
Class of Stock [Line Items]
Warrants to purchase common stock													150,000
Minimum [Member]
Class of Stock [Line Items]
Exercise price of options granted			$ 0.41	$ 0.41
Option vested period			4 years	4 years
Stock issued during period									2,273,329
Maximum [Member]
Class of Stock [Line Items]
Exercise price of options granted			$ 0.44	$ 0.44
Option vested period			5 years	5 years
Stock issued during period									14,776,638
Convertible Promissory Note [Member]
Class of Stock [Line Items]
Warrant exercise price								$ 0.65							$ 1.50	$ 1.50	$ 1.50	$ 1.50
Warrants term								5 years							5 years	5 years	5 years	5 years
Convertible promissory notes					$ 181,500			$ 165,000							$ 200,000	$ 200,000	$ 200,000	$ 200,000
Debt instrument conversion price per share					$ 0.50			$ 0.85									$ 1.50	$ 1.50
Debt principal and accrued interest, amount					$ 211,983
Debt instrument conversion shares					423,966
Shares issued price per share															$ 4	$ 4	$ 4	$ 4
Private Offer Memorandum [Member]
Class of Stock [Line Items]
Common stock sold for cash, shares						300,000
Common stock issued for cash						$ 300,000
Sale of stock price per share						$ 1
Warrants to purchase common stock						161,538
Warrant exercise price						$ 0.01
Warrants term						5 years
Securities Purchase Agreement [Member] \| Private Placement [Member] \| Certain Accredited Investor [Member]
Class of Stock [Line Items]
Stock issued during period	2,910,000	2,000,000
Shares issued price per share	$ 0.50	$ 0.50							$ 0.50
Proceeds from issuance of common stock	$ 1,455,000	$ 1,000,000
Securities Purchase Agreement [Member] \| Private Placement [Member] \| Gary Augusta [Member]
Class of Stock [Line Items]
Stock issued during period	1,000,000
Securities Purchase Agreement [Member] \| Private Placement [Member] \| Nitesh Patel [Member]
Class of Stock [Line Items]
Stock issued during period	40,000
Securities Purchase Agreement [Member] \| Private Placement [Member] \| Shilpa Patel [Member]
Class of Stock [Line Items]
Stock issued during period	20,000

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) (10-K) - USD ($)	1 Months Ended					3 Months Ended		12 Months Ended
Stockholders' Equity (Details Narrative) (10-K) - USD ($)	Nov. 30, 2018	Jul. 31, 2018	Mar. 31, 2017	Feb. 28, 2017	Jan. 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Feb. 28, 2019
Number of common stock issued, value						$ 2,455,000	$ 300,000	$ 800,000	$ 250,000
Warrant purchased from common stock								161,538	87,500
Warrant exercise price				$ 0.01						$ 0.01
Warrants issued				25,000
Warrant grant price				$ 250
Number of shares issued for services			50,000
Number of shares issued for services, value			$ 12,500						$ 12,500
Private Offer Memorandum [Member]
Number of common stock issued	1,000,000	300,000			250,000
Number of common stock issued, value	$ 500,000	$ 300,000			$ 250,000
Sale of stock price per shares	$ 0.50	$ 1			$ 1
Warrant purchased from common stock		161,538			87,500
Warrant exercise price		$ 0.01			$ 0.01
Warrants term		5 years			5 years

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
Warrants (Details Narrative) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Class of Warrant or Right [Line Items]
Number of warrants forfeited		435,000
Warrant [Member]
Class of Warrant or Right [Line Items]
Number of warrants exercised	16,666		25,000
Number of warrants granted	300,000	577,045	115,650
Number of warrants forfeited		(435,000)
Total fair value of warrants issued	$ 269,719
Compensation cost related to warrants	$ 26,363

Warrants (Details Narrative) (1

Warrants (Details Narrative) (10-K) - shares	12 Months Ended
Warrants (Details Narrative) (10-K) - shares	Dec. 31, 2018	Dec. 31, 2017	Feb. 28, 2019	Oct. 15, 2018
Warrant purchased from common stock	161,538	87,500
Warrant issued for renewal of convertible debt	10,000	28,150
Warrants exercised		25,000	16,666
Warrant forfeited of shares	435,000
Community Specialty Pharmacy, LLC [Member]
Warrant purchased from common stock	405,507			405,507
Warrants exercised				405,507

Warrants - Summary of Assumptio

Warrants - Summary of Assumptions Used to Estimate Fair Value of Warrants Granted (Details)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Dividend Yield [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	0	0	0
Expected Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	217		200
Expected Volatility [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input		231
Expected Volatility [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input		632
Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input	2.75
Risk Free Interest Rate [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input		2.55	1.81
Risk Free Interest Rate [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants, measurement input		2.75	1.84
Expected Life of Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, term	5 years		5 years
Expected Life of Warrants [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Warrants, term		5 years
Expected Life of Warrants [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Warrants, term		8 years

Warrants - Schedule of Outstand

Warrants - Schedule of Outstanding and Exercisable Warrants (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Outstanding Shares, Warrants forfeited		435,000
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Outstanding Shares, Warrants Outstanding Beginning	2,880,141	2,738,096	2,647,446
Number of Outstanding Shares, Warrants granted	300,000	577,045	115,650
Number of Outstanding Shares, Warrants forfeited		(435,000)
Number of Outstanding Shares, Warrants exercised	(16,666)		(25,000)
Number of Outstanding Shares, Warrants Outstanding Ending	3,163,475	2,880,141	2,738,096
Weighted Average Exercise Price, Outstanding Beginning	$ 0.08	$ 0.24	$ 0.24
Weighted Average Exercise Price, Warrants granted	0.01	0.02	0.18
Weighted Average Exercise Price, Warrants forfeited
Weighted Average Exercise Price, Warrants exercised	0.01		0.01
Weighted Average Exercise Price, Outstanding Ending	$ 0.08	$ 0.08	$ 0.24
Contractual Life Warrants Outstanding, Beginning	3 years 8 months 26 days	3 years 3 months 11 days	4 years 2 months 27 days
Contractual Life Warrants Outstanding, granted	0 years	7 years 1 month 9 days	5 years
Contractual Life Warrants Outstanding, forfeited	0 years
Contractual Life Warrants Outstanding, exercised	0 years
Contractual Life Warrants Outstanding Ending	3 years 7 days	3 years 8 months 26 days	3 years 3 months 11 days
Aggregate Intrinsic Value Outstanding Beginning	$ 782,385	$ 937,567	$ 930,751
Aggregate Intrinsic Value Outstanding Ending	$ 3,574,954	$ 782,385	$ 937,567

Options (Details Narrative)

Options (Details Narrative) - USD ($)	1 Months Ended				9 Months Ended		12 Months Ended
Options (Details Narrative) - USD ($)	May 31, 2019	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted	505,000	505,000	560,400	253,846	505,000		560,400	263,846
Stock options, forfeited					25,800		(25,400)	(35,000)
Stock options, expired					35,700			(75,000)
Stock options, compensation cost					$ 141,594	$ 133,048	$ 169,828	$ 267,835
Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted					2,000,000		2,000,000
Stock options, description					All options may be exercised for a period of up to four and a half years following the grant date, after which they expire.		All options may be exercised for a period up to four 1/2 years following the grant date, after which they expire.
Stock options, vested period					5 years		5 years

Options (Details Narrative) (10

Options (Details Narrative) (10-K) - USD ($)	1 Months Ended				9 Months Ended		12 Months Ended
Options (Details Narrative) (10-K) - USD ($)	May 31, 2019	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Number of options, granted	505,000	505,000	560,400	253,846	505,000		560,400	263,846
Stock option exercise price, upper range limit			$ 0.50	$ 0.65
Stock option term			10 years	10 years
Stock option vested, description			The options vest over a period of four to five years.	The options vest over a period of one and four years.
Option expense					$ 141,594	$ 133,048	$ 169,828	$ 267,835
Unrecognized compensation costs							$ 192,007
Weighted average period term							6 years 11 months 23 days
Four Option Granted [Member]
Number of options, granted				650,000
Stock option term				10 years
Option expense				$ 69,611
Black-Scholes Option Price Model [Member]
Fair value of options granted							$ 278,358	$ 169,100
Minimum [Member]
Stock option vested period	4 years	4 years
Weighted average period term					5 years		4 years	4 years 8 months 26 days
Maximum [Member]
Stock option vested period	5 years	5 years
Weighted average period term					7 years		5 years	7 years 6 months
Employee [Member]
Number of options, granted							560,400	263,846
Stock option exercise price, lower range limit							$ 0.41	$ 0.41
Stock option exercise price, upper range limit							$ 1.02	$ 1.02
Stock option term							10 years	10 years
Options expire date							Apr. 30, 2028	Apr. 30, 2028
Employee [Member] \| Minimum [Member]
Stock option vested period							4 years	4 years
Employee [Member] \| Maximum [Member]
Stock option vested period							5 years	5 years
Stock Option Plan [Member]
Stock option, description					All options may be exercised for a period of up to four and a half years following the grant date, after which they expire.		All options may be exercised for a period up to four 1/2 years following the grant date, after which they expire.
Stock option vested period					5 years		5 years
Number of options, granted					2,000,000		2,000,000

Options - Schedule of Estimate

Options - Schedule of Estimate Fair Value of Stock Options (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Weighted-average expected volatility, minimum	209.00%	192.00%
Weighted-average expected volatility, maximum	250.00%	265.00%	200.00%
Weighted-average risk-free interest rate, minimum	2.08%	2.08%
Weighted-average risk-free interest rate, maximum	2.55%	2.73%	1.92%
Expected life of options		6 years 11 months 23 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options	5 years	4 years	4 years 8 months 26 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options	7 years	5 years	7 years 6 months

Options - Schedule of Stock Opt

Options - Schedule of Stock Option Activity (Details) - USD ($)	1 Months Ended				9 Months Ended	12 Months Ended
	May 31, 2019	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2017	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Number of Options Outstanding, Beginning Balance					1,732,846	1,197,846	1,044,500
Number of Options Exercisable, Beginning Balance					1,107,259	781,300	584,000
Number of Options, Granted	505,000	505,000	560,400	253,846	505,000	560,400	263,846
Number of Options, Forfeited					25,800	(25,400)	(35,000)
Number of Options, Expired					35,700		(75,000)
Number of Options Outstanding, Ending Balance					2,176,346	1,732,846	1,197,846
Number of Options Exercisable, Ending Balance					1,204,521	1,107,259	781,300
Weighted Average Exercise Price Outstanding, Beginning Balance					$ 1.19	$ 0.97	$ 0.92
Weighted Average Exercise Price Exercisable, Beginning Balance					0.96	1.02	1.05
Weighted Average Exercise Price, Granted					0.43	0.50	0.64
Weighted Average Exercise Price, Forfeited					0.92	0.46	1.02
Weighted Average Exercise Price, Expired					0.60		1.13
Weighted Average Exercise Price Outstanding, Ending Balance					0.73	1.19	0.97
Weighted Average Exercise Price Exercisable, Ending Balance					$ 0.89	$ 0.96	$ 1.02
Contractual Life in Years Outstanding, Beginning Balance	10 years	10 years			6 years 11 months 23 days	6 years 11 months 15 days	3 years 4 months 17 days
Contractual Life in Years Exercisable, Beginning Balance					5 years 10 months 28 days	6 years 3 months 19 days	3 years 7 days
Contractual Life in Years, Granted					0 years	9 years 3 months 4 days	9 years 18 days
Contractual Life in Years, Forfeited					0 years	9 years 22 days	8 years 2 months 30 days
Contractual Life in Years, Expired					0 years	0 years	4 years 6 months 14 days
Contractual Life in Years Outstanding, Ending Balance					7 years 4 days	6 years 11 months 23 days	6 years 11 months 15 days
Contractual Life in Years Exercisable, Ending Balance					5 years 8 months 9 days	5 years 10 months 28 days	6 years 3 months 19 days
Intrinsic Value Outstanding, Beginning Balance
Intrinsic Value Exercisable, Beginning Balance
Intrinsic Value Outstanding, Ending Balance					1,303,547
Intrinsic Value Exercisable, Ending Balance					$ 537,356

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended	9 Months Ended
Leases (Details Narrative)	Sep. 30, 2019USD ($)	Sep. 30, 2019USD ($)Integer
Leases [Abstract]
Operating leases units \| Integer		2
Operating lease amortization of assets	$ 22,658	$ 66,598
Operating lease amortization of liabilities	$ 18,826	$ 55,102

Leases - Schedule of Operating

Leases - Schedule of Operating Leases (Details) - USD ($)	9 Months Ended
Leases - Schedule of Operating Leases (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Lessee, Lease, Description [Line Items]
Initial Recognition of Right to use assets at January 1, 2019	$ 780,843
Lease 1 [Member]
Lessee, Lease, Description [Line Items]
Initial Lease Term	December 2017 to December 2021
Renewal Term	January 2021 to December 2024
Initial Recognition of Right to use assets at January 1, 2019	$ 534,140
Incremental Borrowing Rate	10.00%
Lease 2 [Member]
Lessee, Lease, Description [Line Items]
Initial Lease Term	November 2018 to November 2023
Renewal Term	November 2023 to November 2028
Initial Recognition of Right to use assets at January 1, 2019	$ 313,301
Incremental Borrowing Rate	10.00%

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments for Operating Lease Liabilities (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Leases [Abstract]
2019	$ 159,538
2020	164,299
2021	169,223
2022	174,320
2023	179,552
Thereafter	259,858
Total minimum lease payments	1,106,790
Less: effect of discounting	(314,451)
Present value of future minimum lease payments	792,339
Less: current obligations under leases	84,050
Long-term lease obligations	$ 708,289

Income Taxes (Details Narrative

Income Taxes (Details Narrative) (10-K)	12 Months Ended
Income Taxes (Details Narrative) (10-K)	Dec. 31, 2018USD ($)
Income Tax Disclosure [Abstract]
Federal corporate income tax rate	21.00%
Income tax, description	On December 22, 2017 H.R. 1, originally known as the Tax Cuts and Jobs Act, (the "Tax Act") was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate ("Federal Tax Rate") from 35% to 21% effective January 1, 2018.
Net operating loss carry forwards	$ 4,400,000

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) (10-K) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Federal loss carry forwards	$ 922,850	$ 963,833
Less: valuation allowance	(922,850)	(963,833)
Deferred tax assets

Related Parties (Details Narrat

Related Parties (Details Narrative) (10-K) - USD ($)	1 Months Ended			12 Months Ended
Related Parties (Details Narrative) (10-K) - USD ($)	Oct. 31, 2018	Jan. 31, 2018	Jan. 31, 2017	Dec. 31, 2017	Dec. 31, 2018
Convertible promissory notes				$ 181,500
Debt instrument maturity date				May 31, 2019
Community Specialty Pharmacy, LLC [Member]
Convertible promissory notes	$ 300,000
Debt instrument maturity date	Oct. 15, 2021
Interest rate	10.00%
Mr. Suren Ajjarapu [Member]
Executive salaries		$ 200,000	$ 165,000
Mr. Prashant Patel [Member]
Executive salaries		$ 150,000	$ 125,000
Due to related parties				$ 62,500	$ 0

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) (10-K)	12 Months Ended
Commitments and Contingencies (Details Narrative) (10-K)	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Operating lease description	The Company leases two premises in Land O' Lakes, Florida under an operating lease that expires in 2021 and in Tampa, Florida under an operating lease that expires in 2023.

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payments Under Non-cancelable Operating Leases (Details) (10-K)	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 156,024
2020	160,709
2021	165,506
2022	49,080
2023	41,934
Total	$ 573,253

Segment Reporting - Schedule of

Segment Reporting - Schedule of Business Interests Into Reportable Segments (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 2,311,426	$ 847,471	$ 5,740,361	$ 2,538,082	$ 3,831,778	$ 2,931,280
Gross Profit	1,310,509	$ 845,126	3,620,467	$ 2,535,737	3,382,729	2,931,280
Segment Assets	5,854,523		5,854,523		2,227,587	$ 617,476
Segment Profit/Loss			210,775
Trxade, Inc. [Member]
Segment Reporting Information [Line Items]
Revenue			3,335,050		3,407,822
Gross Profit					3,407,822
Segment Assets	1,561,760		1,561,760		822,412
Segment Profit/Loss			1,748,896		1,371,615
Community Specialty Pharmacy, LLC [Member]
Segment Reporting Information [Line Items]
Revenue			1,412,449		395,418
Gross Profit					(34,971)
Segment Assets	315,681		315,681		112,123
Segment Profit/Loss			(75,955)		(116,588)
Integra Pharma, LLC [Member]
Segment Reporting Information [Line Items]
Revenue			992,862
Segment Assets	411,161		411,161
Segment Profit/Loss			(122,144)
Other [Member]
Segment Reporting Information [Line Items]
Revenue
Segment Assets	$ 3,565,921		3,565,921
Segment Profit/Loss			$ (1,340,022)
Other [Member]
Segment Reporting Information [Line Items]
Revenue					28,538
Gross Profit					9,878
Segment Assets					1,293,052
Segment Profit/Loss					$ (1,245,989)

Business Combination (Details N

Business Combination (Details Narrative) - USD ($)	Oct. 15, 2018	Sep. 30, 2019	Feb. 28, 2019	Dec. 31, 2018	Dec. 31, 2017	Feb. 28, 2017
Business Acquisition [Line Items]
Equity method investment ownership percentage		100.00%		100.00%
Warrants to purchase common stock			16,666		25,000
Warrant strike price			$ 0.01			$ 0.01
Goodwill		$ 725,973		$ 725,973
Community Specialty Pharmacy, LLC [Member]
Business Acquisition [Line Items]
Equity method investment ownership percentage	100.00%
Purchase price, cash	$ 300,000
Promissory note issued	$ 300,000
Warrants to purchase common stock	405,507
Warrant term	8 years
Warrant strike price	$ 0.01
Exercise restrictions lapse period	3 years
Goodwill	$ 725,973
Total purchase price	770,291
Fair value of warrants issued	$ 170,291

Business Combination (Details_2

Business Combination (Details Narrative) (10-K) - USD ($)	Oct. 15, 2018	Sep. 30, 2019	Feb. 28, 2019	Dec. 31, 2018	Dec. 31, 2017	Feb. 28, 2017
Equity method investment ownership percentage		100.00%		100.00%
Number of shares entitled for warrants issued				161,538	87,500
Warrant exercise price			$ 0.01			$ 0.01
Goodwill		$ 725,973		$ 725,973
Community Specialty Pharmacy, LLC [Member]
Equity method investment ownership percentage	100.00%
Purchase price, cash	$ 300,000
Promissory note issued	$ 300,000
Number of shares entitled for warrants issued	405,507			405,507
Warrant term	8 years
Warrant exercise price	$ 0.01
Exercise restrictions lapse period	3 years
Goodwill	$ 725,973
Total purchase price	770,291
Fair value of warrants	$ 170,291

Business Combination - Schedule

Business Combination - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Oct. 15, 2018	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill		$ 725,973	$ 725,973
Community Specialty Pharmacy, LLC [Member]
Business Acquisition [Line Items]
Purchase Price	$ 770,291
Cash	(49,728)
Accounts Receivable	(114,899)
Inventory	(76,156)
Prepaid	(3,000)
Accounts Payable	199,312
Accrued Expenses	153
Goodwill	$ 725,973

Business Combination - Schedu_2

Business Combination - Schedule of Unaudited Pro Forma Statements of Operations (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Revenue	$ 1,509,974	$ 4,523,702	$ 5,823,996	$ 5,565,194
Net Income	$ 203,805	$ 294,402	$ 118,903	$ 225,851
Net Income per common share - basic	$ 0.01	$ 0.01	$ 0	$ 0.01
Net Income per common share - diluted	$ 0.01	$ 0.01	$ 0	$ 0.01
Weighted average common shares - basic	32,083,629	32,083,629	32,260,622	31,955,416
Weighted average common shares - diluted	34,737,964	34,732,540	34,958,502	34,086,251
Trxade [Member]
Business Acquisition [Line Items]
Revenue	$ 847,471	$ 2,538,082	$ 3,436,360	$ 2,931,280
Net Income	$ 94,249	$ 197,031	$ 125,626	$ 288,983
Net Income per common share - basic	$ 0	$ 0.01	$ 0	$ 0.01
Net Income per common share - diluted	$ 0	$ 0.01	$ 0	$ 0.01
Weighted average common shares - basic	32,083,629	32,083,629	32,260,622	31,955,416
Weighted average common shares - diluted	34,737,964	34,732,540	34,958,502	34,086,251
Community Specialty Pharmacy, LLC [Member]
Business Acquisition [Line Items]
Revenue	$ 662,503	$ 1,985,620	$ 2,387,636	$ 2,633,914
Net Income	$ 109,556	$ 97,371	$ (6,723)	$ (63,132)

Equity Method Investment (Detai

Equity Method Investment (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Apr. 30, 2019

Jan. 31, 2019

Sep. 30, 2019

Mar. 31, 2019

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Dec. 31, 2017

Jan. 31, 2020

Nov. 01, 2019

Aug. 01, 2019

May 01, 2019

Schedule of Equity Method Investments [Line Items]

Payment to acquire equity interest

$ 250,000

Equity method investment ownership percentage

100.00%

Equity method investment loss

$ 162,178

$ 250,000

Minimum [Member]

Schedule of Equity Method Investments [Line Items]

Stock issued during period

2,273,329

Maximum [Member]

Schedule of Equity Method Investments [Line Items]

Stock issued during period

14,776,638

Subsequent Event [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment ownership percentage

30.00%

SyncHealth MSO, LLC [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment ownership percentage

6.00%

SyncHealth MSO, LLC [Member] | Subsequent Event [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment ownership percentage

7.00%

Alliance Pharma Solution, LLC [Member]

Schedule of Equity Method Investments [Line Items]

Payment to acquire equity interest

$ 40,000

$ 250,000

$ 210,000

Equity method investment ownership percentage

49.00%

Equity method investment

$ 0

Alliance Pharma Solution, LLC [Member] | Technology [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment loss

Alliance Pharma Solution, LLC [Member] | Subsequent Event [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment ownership percentage

49.00%

Alliance Pharma Solution, LLC [Member] | SyncHealth MSO, LLC [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment ownership percentage

30.00%

Alliance Pharma Solution, LLC [Member] | SyncHealth MSO, LLC [Member] | Subsequent Event [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment ownership percentage

30.00%

PanOptic Health, LLC [Member] | SyncHealth MSO, LLC [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment ownership percentage

70.00%

PanOptic Health, LLC [Member] | SyncHealth MSO, LLC [Member] | Subsequent Event [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment ownership percentage

70.00%

SyncHealth MSO, LLC [Member] | Forecast [Member]

Schedule of Equity Method Investments [Line Items]

Equity method investment ownership percentage

51.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Oct. 23, 2019USD ($)Integershares	Oct. 08, 2019USD ($)	Oct. 31, 2019USD ($)$ / sharesshares	Feb. 28, 2019$ / sharesshares	Sep. 30, 2019USD ($)shares	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Subsequent Event [Line Items]
Repayments of related party debt \| $					$ 40,000	$ 111,725
Debt instrument maturity date								May 31, 2019
Maximum [Member]
Subsequent Event [Line Items]
Stock issued during period \| shares					14,776,638
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt instrument conversion amount \| $			$ 175,000
Debt instrument conversion shares \| shares			350,000	423,966
Debt instrument conversion price per share \| $ / shares			$ 0.50
Write down value of assets \| $	$ 359,000
Subsequent Event [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Debt instrument conversion price per share \| $ / shares				$ 0.85
Subsequent Event [Member] \| Mr. Prashant Patel [Member]
Subsequent Event [Line Items]
Repayments of related party debt \| $		$ 122,552
Debt instrument maturity date		Jul. 1, 2020
Subsequent Event [Member] \| Mr. Suren Ajjarapu [Member]
Subsequent Event [Line Items]
Repayments of related party debt \| $		$ 100,000
Debt instrument maturity date		Jul. 1, 2020
Subsequent Event [Member] \| Bonum Health, LLC [Member]
Subsequent Event [Line Items]
Number of restricted stock \| shares	250,000
Subsequent Event [Member] \| Bonum Health, LLC [Member] \| Asset Purchase Agreement [Member]
Subsequent Event [Line Items]
Agreement non-compete requirement term	3 years
Minimal claim amount \| $	$ 25,000
Subsequent Event [Member] \| Bonum Health, LLC [Member] \| Maximum [Member] \| Asset Purchase Agreement [Member]
Subsequent Event [Line Items]
Amount for installation and milestone payments \| $	$ 600,000
Subsequent Event [Member] \| Bonum Health, LLC [Member] \| APA Shares [Member] \| 40 In-Store Wellness Kiosks [Member]
Subsequent Event [Line Items]
Stock issued during period \| shares	240,000
Number of in-store wellness kiosks \| Integer	40
Subsequent Event [Member] \| Bonum Health, LLC [Member] \| APA Shares [Member] \| 70 In-Store Wellness Kiosks [Member]
Subsequent Event [Line Items]
Stock issued during period \| shares	205,000
Number of in-store wellness kiosks \| Integer	70
Subsequent Event [Member] \| Bonum Health, LLC [Member] \| APA Shares [Member] \| 100 In-Store Wellness Kiosks [Member]
Subsequent Event [Line Items]
Stock issued during period \| shares	205,000
Number of in-store wellness kiosks \| Integer	100
Subsequent Event [Member] \| Bonum Health, LLC [Member] \| APA Shares [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Number of restricted stock \| shares	650,000

Subsequent Events (Details Na_2

Subsequent Events (Details Narrative) (10-K) - USD ($)	1 Months Ended			9 Months Ended		12 Months Ended
Subsequent Events (Details Narrative) (10-K) - USD ($)	Oct. 31, 2019	Feb. 28, 2019	Jan. 31, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Nov. 01, 2019	Aug. 01, 2019	May 01, 2019	Feb. 28, 2017
Equity method investment ownership percentage				100.00%		100.00%
Warrants issued											25,000
Warrant exercise price		$ 0.01									$ 0.01
Value of common stock shares converted				$ 211,983
SyncHealth MSO, LLC [Member]
Equity method investment ownership percentage									6.00%	6.00%
Alliance Pharma Solution, LLC [Member]
Equity method investment ownership percentage			49.00%
Alliance Pharma Solution, LLC [Member] \| SyncHealth MSO, LLC [Member]
Equity method investment ownership percentage			30.00%
Alliance Pharma Solution, LLC [Member] \| SyncHealth MSO, LLC [Member] \| May 1, 2019 [Member]
Equity method investment ownership percentage						6.00%
Alliance Pharma Solution, LLC [Member] \| SyncHealth MSO, LLC [Member] \| August 1, 2019 [Member]
Equity method investment ownership percentage						6.00%
Alliance Pharma Solution, LLC [Member] \| SyncHealth MSO, LLC [Member] \| November 1, 2019 [Member]
Equity method investment ownership percentage						7.00%
Alliance Pharma Solution, LLC [Member] \| SyncHealth MSO, LLC [Member] \| January 31, 2020 [Member]
Equity method investment ownership percentage						51.00%
PanOptic Health, LLC [Member] \| SyncHealth MSO, LLC [Member]
Equity method investment ownership percentage			70.00%
Subsequent Event [Member]
Equity method investment ownership percentage			30.00%
Business combination consideration transferred			$ 250,000
Promissory note issued amount		$ 150,000
Conversion price of promissory note	$ 0.50
Principal and accrued interest		$ 211,983
Conversion of convertible debt, converted number of shares	350,000	423,966
Warrants issued		16,666
Warrant exercise price		$ 0.01
Number of common stock shares converted		16,666
Value of common stock shares converted		$ 166
Subsequent Event [Member] \| Maximum [Member]
Conversion price of promissory note		$ 0.85
Subsequent Event [Member] \| Minimum [Member]
Conversion price of promissory note		$ 0.50
Subsequent Event [Member] \| SyncHealth MSO, LLC [Member]
Equity method investment ownership percentage								7.00%
Subsequent Event [Member] \| Alliance Pharma Solution, LLC [Member]
Shares transferred			250,000
Equity method investment ownership percentage			49.00%
Subsequent Event [Member] \| Alliance Pharma Solution, LLC [Member] \| SyncHealth MSO, LLC [Member]
Equity method investment ownership percentage			30.00%
Subsequent Event [Member] \| PanOptic Health, LLC [Member] \| SyncHealth MSO, LLC [Member]
Equity method investment ownership percentage			70.00%